WO2022192503A1 - Heptamethine carbocyanine dye-cross-bridged tetraamine cyclam (ctc) chelator conjugates, their stable complexes with copper-64, and uses thereof - Google Patents
Heptamethine carbocyanine dye-cross-bridged tetraamine cyclam (ctc) chelator conjugates, their stable complexes with copper-64, and uses thereof Download PDFInfo
- Publication number
- WO2022192503A1 WO2022192503A1 PCT/US2022/019695 US2022019695W WO2022192503A1 WO 2022192503 A1 WO2022192503 A1 WO 2022192503A1 US 2022019695 W US2022019695 W US 2022019695W WO 2022192503 A1 WO2022192503 A1 WO 2022192503A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- complexes
- cancer
- chelator
- imaging
- ctc
- Prior art date
Links
- 239000002738 chelating agent Substances 0.000 title claims abstract description 57
- 239000000298 carbocyanine Substances 0.000 title claims abstract description 12
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 title claims abstract description 11
- KSSJBGNOJJETTC-UHFFFAOYSA-N COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC Chemical compound COC1=C(C=CC=C1)N(C1=CC=2C3(C4=CC(=CC=C4C=2C=C1)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC(=CC=C1C=1C=CC(=CC=13)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)N(C1=CC=C(C=C1)OC)C1=C(C=CC=C1)OC)C1=CC=C(C=C1)OC KSSJBGNOJJETTC-UHFFFAOYSA-N 0.000 title claims abstract description 10
- RYGMFSIKBFXOCR-IGMARMGPSA-N copper-64 Chemical compound [64Cu] RYGMFSIKBFXOCR-IGMARMGPSA-N 0.000 title abstract description 8
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 226
- 238000003384 imaging method Methods 0.000 claims abstract description 80
- 201000011510 cancer Diseases 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 60
- 108700013553 diamsar chelate Proteins 0.000 claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- UQQQAKFVWNQYTP-UHFFFAOYSA-N 3,6,10,13,16,19-hexazabicyclo[6.6.6]icosane-1,8-diamine Chemical compound C1NCCNCC2(N)CNCCNCC1(N)CNCCNC2 UQQQAKFVWNQYTP-UHFFFAOYSA-N 0.000 claims abstract description 23
- SYFGLWDDLZQFNI-UHFFFAOYSA-N 2-[4-(carboxymethyl)-1,4,8,11-tetrazabicyclo[6.6.2]hexadecan-11-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCCN2CCN(CC(=O)O)CCCN1CC2 SYFGLWDDLZQFNI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 210000004027 cell Anatomy 0.000 claims description 62
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 46
- 238000002560 therapeutic procedure Methods 0.000 claims description 46
- 238000011282 treatment Methods 0.000 claims description 35
- 238000002600 positron emission tomography Methods 0.000 claims description 31
- 125000005647 linker group Chemical group 0.000 claims description 25
- -1 or alternatively Chemical group 0.000 claims description 21
- 238000002591 computed tomography Methods 0.000 claims description 18
- 230000005855 radiation Effects 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 206010060862 Prostate cancer Diseases 0.000 claims description 16
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 16
- 239000000872 buffer Substances 0.000 claims description 14
- 239000004472 Lysine Substances 0.000 claims description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 12
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims description 11
- 206010029260 Neuroblastoma Diseases 0.000 claims description 11
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 8
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 8
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 8
- 230000004077 genetic alteration Effects 0.000 claims description 7
- 231100000118 genetic alteration Toxicity 0.000 claims description 7
- 102000040848 ETS family Human genes 0.000 claims description 6
- 108091071901 ETS family Proteins 0.000 claims description 6
- 108091023040 Transcription factor Proteins 0.000 claims description 6
- 102000040945 Transcription factor Human genes 0.000 claims description 6
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 230000000536 complexating effect Effects 0.000 claims description 3
- 238000003325 tomography Methods 0.000 claims description 3
- 230000000955 neuroendocrine Effects 0.000 claims description 2
- 239000010949 copper Substances 0.000 abstract description 68
- 239000000203 mixture Substances 0.000 abstract description 57
- 206010027476 Metastases Diseases 0.000 abstract description 36
- 238000001959 radiotherapy Methods 0.000 abstract description 32
- 210000002966 serum Anatomy 0.000 abstract description 22
- 230000008685 targeting Effects 0.000 abstract description 20
- 239000012217 radiopharmaceutical Substances 0.000 abstract description 13
- 229940121896 radiopharmaceutical Drugs 0.000 abstract description 13
- 230000002799 radiopharmaceutical effect Effects 0.000 abstract description 13
- 238000009472 formulation Methods 0.000 abstract description 12
- 150000001879 copper Chemical class 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 45
- 210000000056 organ Anatomy 0.000 description 43
- 150000001875 compounds Chemical class 0.000 description 27
- 230000000694 effects Effects 0.000 description 24
- 210000003734 kidney Anatomy 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 23
- 239000000243 solution Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 21
- 210000004185 liver Anatomy 0.000 description 21
- 239000007924 injection Substances 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- 230000015572 biosynthetic process Effects 0.000 description 19
- 239000008280 blood Substances 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 239000002904 solvent Substances 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 208000003174 Brain Neoplasms Diseases 0.000 description 15
- 210000000988 bone and bone Anatomy 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 14
- 230000035515 penetration Effects 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 238000009826 distribution Methods 0.000 description 12
- 238000000163 radioactive labelling Methods 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 208000034951 Genetic Translocation Diseases 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 230000037396 body weight Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 235000018977 lysine Nutrition 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 231100000419 toxicity Toxicity 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000012879 PET imaging Methods 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000007920 subcutaneous administration Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000002562 thickening agent Substances 0.000 description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 239000003937 drug carrier Substances 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 210000002216 heart Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000010172 mouse model Methods 0.000 description 8
- 230000002285 radioactive effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 7
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 7
- 241000699660 Mus musculus Species 0.000 description 7
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 208000005017 glioblastoma Diseases 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000009401 metastasis Effects 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 229920001223 polyethylene glycol Chemical group 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000011581 secondary neoplasm Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 206010003571 Astrocytoma Diseases 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 230000035508 accumulation Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 229960002725 isoflurane Drugs 0.000 description 5
- 239000006201 parenteral dosage form Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000007909 solid dosage form Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 description 4
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 231100000987 absorbed dose Toxicity 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 235000003704 aspartic acid Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002349 favourable effect Effects 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 235000013922 glutamic acid Nutrition 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000004007 reversed phase HPLC Methods 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100032187 Androgen receptor Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 108010080146 androgen receptors Proteins 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000003560 cancer drug Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000009918 complex formation Effects 0.000 description 3
- 238000013170 computed tomography imaging Methods 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GDIYMWAMJKRXRE-UHFFFAOYSA-N (2z)-2-[(2e)-2-[2-chloro-3-[(z)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole Chemical compound CC1(C)C2=CC=CC=C2N(C)C1=CC=C1C(Cl)=C(C=CC=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC1 GDIYMWAMJKRXRE-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- FLHJIAFUWHPJRT-UHFFFAOYSA-N 2,3,3-trimethylindole Chemical compound C1=CC=C2C(C)(C)C(C)=NC2=C1 FLHJIAFUWHPJRT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 206010073140 Clear cell sarcoma of soft tissue Diseases 0.000 description 2
- 102100035595 Cohesin subunit SA-2 Human genes 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 101000642968 Homo sapiens Cohesin subunit SA-2 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000581650 Ivesia Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Chemical group 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 101150113664 RGG2 gene Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000002725 brachytherapy Methods 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 201000000292 clear cell sarcoma Diseases 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002939 deleterious effect Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 2
- 208000023958 prostate neoplasm Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000036326 tumor accumulation Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 238000009827 uniform distribution Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- NVRVNSHHLPQGCU-UHFFFAOYSA-N 6-bromohexanoic acid Chemical compound OC(=O)CCCCCBr NVRVNSHHLPQGCU-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical group OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 102100023026 Cyclic AMP-dependent transcription factor ATF-1 Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000008743 Desmoplastic Small Round Cell Tumor Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101150025421 ETS gene Proteins 0.000 description 1
- 239000004131 EU approved raising agent Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000003364 Extraskeletal myxoid chondrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000938536 Homo sapiens RNA-binding protein EWS Proteins 0.000 description 1
- 101001099181 Homo sapiens TATA-binding protein-associated factor 2N Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010051696 Metastases to meninges Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010073137 Myxoid liposarcoma Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010073338 Optic glioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
- 206010036909 Prostate cancer metastatic Diseases 0.000 description 1
- 102100040923 Protein flightless-1 homolog Human genes 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 101150056997 RGG1 gene Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 108700020471 RNA-Binding Proteins Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000008938 Rhabdoid tumor Diseases 0.000 description 1
- 206010073334 Rhabdoid tumour Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102100038917 TATA-binding protein-associated factor 2N Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005781 adult medulloblastoma Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 231100000976 cerebrotoxicity Toxicity 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 229940127043 diagnostic radiopharmaceutical Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000010855 food raising agent Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 208000026436 grade III glioma Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000053502 human EWSR1 Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 208000023525 immature teratoma Diseases 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 201000000573 juvenile pilocytic astrocytoma Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000006233 lamp black Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000008511 optic nerve glioma Diseases 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- MHYFEEDKONKGEB-UHFFFAOYSA-N oxathiane 2,2-dioxide Chemical compound O=S1(=O)CCCCO1 MHYFEEDKONKGEB-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 231100000974 spleenotoxicity Toxicity 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940127044 therapeutic radiopharmaceutical Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000155 toxicity by organ Toxicity 0.000 description 1
- 230000007675 toxicity by organ Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000759 toxicological effect Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000008136 water-miscible vehicle Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
- C09B23/0066—Methine or polymethine dyes, e.g. cyanine dyes the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)
Definitions
- Embodiments of the present invention generally relate to conjugates of the near infrared (NIR) heptamethine carbocyanine dye (HMCD) with chelator-radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, e.g. in internal radiotherapy and/or imaging of cancer.
- NIR near infrared
- HMCD heptamethine carbocyanine dye
- chelator-radiometal complexes e.g. in internal radiotherapy and/or imaging of cancer.
- CTC DZ-1 -cross- bridged tetraamine cyclam conjugates with optional linker L (DZ-l-(L)-CTC), wherein the CTC chelator is complexed with copper-64 ( 64 Cu).
- the CTC may be a chelator selected from the group comprising CB-TE2A, DiAmSar, derivatives or combinations thereof.
- Copper complexes comprising DZ-1-(L)-CTC may provide improved serum stability compared to previously known copper complexes while retaining tumor targeting and providing good imaging quality.
- the present invention also relates to methods of forming the complexes, pharmaceutical compositions comprising the complexes, methods of using the complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, soft and solid tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like.
- Advantages of the embodiments may further include improved imaging and/or tumor detection, improved therapy of tumors, cancer, metastases, and pre-cancerous lesions, improved image guided therapy, and improved penetration of tumors, especially solid tumors.
- the complexes may allow to treat aggressive tumors that have few or no treatment options, particularly small round cell tumors, including tumors such as Ewing’s sarcoma (EWS), neuroblastoma, small cell lung cancer, Merkel cell tumors, and hormone-refractory prostate cancer (HRPC).
- EWS Ewing’s sarcoma
- HRPC hormone-refractory prostate cancer
- Radiometals can be delivered by chelating or complexing them with a large variety of chelator compounds and conjugating them to a targeting ligand.
- Radionuclide complexes currently used for such targeted radiotherapy are mostly diagnostic, with a limited number of therapeutic applications.
- the latter include various antibodies, proteins, and some smaller compounds, in particular peptides that are able to target certain types of cancer.
- radionuclides and radiometals for tumor imaging or adding imaging functionality to targeted cancer drugs include certain dye conjugates, namely near infrared (NIR) heptamethine carbocyanine dye (HMCD) conjugates. These were described for targeted cancer drug therapy and imaging, e.g. in WO 2016106324 and US 10,307,489 and include double-conjugated dye-drug-chelator conjugates wherein the dye is conjugated to a) anti cancer drug gemcitabine as well as b) an imaging moiety; one such imaging moiety is 64 Cu- DOTA.
- the chelated/complexed radiometals are employed to provide imaging functionality to the cancer drug conjugates.
- a lysine-linked heptamethine carbocyanine dye conjugated with DOTA and complexed with Cu-64 was also described for imaging of cancer by Xiao et ah, Nuclear Medicine and Biology 40, p. 351-360 (2013) and e.g. in WO2016106324.
- a problem with known radiometal complexes can be a lack of stability in the body, e.g. in blood and/or serum, which may result in insufficient performance, in particular in imaging performance and/or poor imaging quality (e.g. low signal strength, high noise, low signal/noise ratio, and/or resolution) when trying to detect small secondary tumors or metastases, as well as low efficacy and unnecessarily high radiation exposure with associated side effect and damage to non-cancerous tissues and organs.
- imaging quality e.g. low signal strength, high noise, low signal/noise ratio, and/or resolution
- Particular problems of copper radiometal chelates include poor bio-distribution and/or poor stability in vivo mediated by the chelator or radiometal or their combination, and which may be caused by dissociation of copper from the chelator and/or binding of non-target tissues.
- Some chelates are subject to retention in non-target tissues such as the liver, kidney or other organs.
- Dissociation and binding of 64 Cu may prevent targeting to cancer cells or tumors as intended, and instead target, or rather, re-direct, 64 Cu to other non-cancerous parts of the body and expose these parts to harmful radiation.
- Some radiometal chelates (or their dissociated products) show activity in other organs, e.g. liver, kidney, blood, bone, and/or bone marrow.
- 64 Cu may bind to other proteins if the chelate-biomolecules were not sufficiently stable either kinetically and/or thermodynamically.
- Still further problems with radiochemicals may include one or more of: lack of suitability for therapy for one or more cancer, insufficient sensitivity, insufficient selectivity for cancer cells, insufficient contrast between tumor and noncancerous tissues over time, insufficient biodistribution, insufficient tumor targeting, insufficient tissue and/or tumor penetration, insufficiently uniform distribution in tumor tissues, insufficient tumor accumulation ratios, insufficient retention in the tumor, slow clearance from the blood after administration, undesirably high radioactive exposure of tissues and organs, low clearance rate from important organs such as kidney, liver, heart etc., high radiation damage of non-targeted tissues or organs, in particular encapsulated tissues such as organs and dense tissues including tumor tissues, in particular calcified tumor tissues, slow establishment of steady state distribution in the body and organs including heart, liver, lungs and kidney, persistence of radioactivity in one or more organs including kidney and/or liver, no stable complex formation with one or more radiometal or difficulties to form stable complexes, low complex formation rates, low labelling efficiency with one or more radio
- Radiotherapy tends to be even more challenging than mere imaging applications and options for treatment by radiotherapy are thus much more limited.
- Careful integration is needed for a suitable radionuclide in combination with a suitable chelator and a suitable targeting ligand to provide the desired characteristics including affinity, stability and pharmacokinetics.
- Particular radiometals may emit one or more type of particles or radiation at particular different percentages, and for suitable targeting careful coordination of carrier with a given radiometal is needed so that the complex is stable, sufficiently effective to destroy the target cancer but arrives at the location without causing collateral radiation damage to the not targeted rest of the body and its organs and tissues.
- Some therapeutics can provide both therapy and diagnostic imaging to a degree, though for improved performance of each, theranostic pairs are often employed.
- a “true” theranostic pair would be an identical matched pair, i.e. have the same carrier for the therapeutic radiometal to destroy the tumor, and the imaging radiometal to allow to diagnostic and/or guided therapy.
- both chelator and radiometal affect important performance characteristics and pharmacokinetics, thus a given carrier may not be able to provide an identically matched pair with suitable characteristics, stability and efficacy for a desired radiometal combination.
- a non-identical matched pair may be used to adjust characteristics, provided that the binding affinities do not present clinically significant differences.
- Agents or pairs of agents that can provide theranostic functionality thus often lack true theranostic functionality or other desirable characteristics, i.e. the ability to provide both sufficient therapeutic effect and sufficiently high imaging sensitivity at the same time and at similar pharmacokinetics, as well as favorable general pharmacokinetics, a high cytotoxicity for cancer cells but a low toxicity for non-cancerous cells.
- a particular problem of radiochemicals is a high and persistent localization of the radioactivity being observed in certain organs, for example, without limitation, the kidneys, the liver, etc., which compromises tumor visualization in the region of the affected organ and limits therapeutic potential, e.g. for kidney or liver tumors and tumors localized in their area.
- Radionuclide complexes also may encounter resorption by proximal tubules of the kidneys and/or adverse long residence times of radiometabolites in cells, particularly in renal cells, or cells of other organs, which may cause undesirably persistent radioactivity.
- radiopharmaceuticals that can provide improved radioimaging and/or improved radiotherapy, or both, and for radiopharmaceuticals with improved characteristics.
- radiopharmaceuticals with improved stability in particular serum stability, reduced toxicity, increased effectiveness, and/or increased tumor penetration, favorable pharmacokinetics, among others.
- theranostics that at allow both efficient therapy and imaging at the same time.
- therapeutics, imaging agents and theranostics that reduce or avoid damage to non-cancerous cells and tissues.
- a DZ-1-(L)-CTC conjugate wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with an optional linker moiety L and a cross-bridged tetraamine cyclam (CTC) chelator residue R and as shown in FI below: wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from the group consisting of CB- TE2A, DiAmSar, or a derivative thereof, wherein the optional linker L is a residue selected from the group comprising a Lysine residue, and wherein the chelator residue is complexed with 64Cu.
- HMCD heptamethine carbocyanine dye
- CTC cross-bridged tetraamine cyclam
- R is CB-TE2A
- L is a lysine residue which links DZ-1 to the chelator as shown in FII below:
- R is DiAmSar as shown in Fill below:
- a complex provided with one or more pharmaceutically acceptable excipient to form a pharmaceutical formulation.
- a complex provided as a kit with one or more reagents for reconstitution of the complex in an administrable form.
- kits provided with instructions for mixing and complexing the conjugate and 64Cu in suitable amounts, optionally with one or more reagent, buffer or excipient, and optionally treating the resulting solution containing the formed complex to provide it in an administrable form.
- a DZ-1- Lys-chelator conjugate complex of formula FI is administered to a subject suffering from cancer or from a risk to develop cancer in a sufficient amount and for sufficient duration to allow imaging or treatment; wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with a chelator residue R via a lysine linker and as shown in formula FI herein-above, wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from CB- TE2A, DiAmSar, or a derivative thereof, and wherein the chelator residue is complexed with 64Cu.
- HMCD heptamethine carbocyanine dye
- R is CB-TE2A
- L is a lysine residue which links DZ-1 to the chelator as shown in FII herein-above
- DZl-Lys-CB- TE2A DiAmSar as shown in Fill herein above
- imaging is performed by Positron Emission Tomography (PET) or Single-Photon Emission Computerized Tomography (SPECT) to detect 64Cu radiation, and optionally additionally by Computer Tomography (CT).
- PET Positron Emission Tomography
- SPECT Single-Photon Emission Computerized Tomography
- CT Computer Tomography
- imaging is performed before and/or during one or more therapy time intervals to provide an image-guided therapy.
- a method wherein the risk to develop cancer is one or more genetic alteration associated with EWS, and the alterations include one or more alteration to a member of the ETS family of transcription factors.
- EWS Ewing’s Sarcoma
- a small cell round tumor adult neuroblastoma, neuroblastoma in children
- small cell lung cancer Merkel cell tumors
- Merkel cell tumors of the skin prostate cancer
- HRPC hormone-refractory prostate cancer
- NE-HRPC neuroendocrine differentiated HRPC
- pre-B-cell acute lymphoblastic leukemia pre-B-cell acute lymphoblastic leukemia
- EWS Ewing’s Sarcoma
- R is CB-TE2A, or a derivative thereof.
- R is DiAmSar, or a derivative thereof.
- Fig. 1 illustrates a radio-HPLC analysis of 64 Cu-DZ-l-Lys-CB-TE2A.
- the top panel shows the UV channel at 780 nm, and the bottom panel shows the radio-channel. Fractions from 10 - 12 min contain the probe and were collected and pooled for use in Example 10.
- Fig. 2 illustrates the high serum stability of 64 Cu-DZ-l-Lys-CB-TE2A measured by radio- Thin Layer Chromatography (TLC) over time in hours in serum at 37°C (> 95%).
- TLC Thin Layer Chromatography
- Fig. 3 illustrates the Standardized Uptake Value (SUV) observed in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts, ranging from about 2.5 or more at 4h to between about 0.5 to about 2.5 at 24h, and about 0.125 at 48h (i.e. substantially clearance from the body and its organs).
- SUV Standardized Uptake Value
- Fig. 4 A illustrates a substantial tumor uptake and retention, good signal-to-noise ratio and high specificity observed at 4 h in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts.
- Fig. 4 B illustrates a substantial tumor uptake and retention, good signal-to-noise ratio and high specificity observed at 24 h in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts.
- Fig. 4 C illustrates an efficient clearance profile including from the kidneys at 48 h (compare to 24 h in Fig. 4 B).
- Fig. 5 A illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64 Cu-DZ-l-CB-TE2A in tumors at 4 h.
- MIP maximum intensity projection
- Fig. 5 B illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64 Cu-DZ-l-CB-TE2A in tumors at 24 h.
- MIP maximum intensity projection
- Fig. 5 C illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64 Cu-DZ-l-CB-TE2A in tumors at 48 h.
- MIP maximum intensity projection
- Fig. 6 illustrates low signal strength of Cu 64 -DZ-l-NOTA in a PC3 subcutaneous model.
- Fig. 7 A illustrates low signal-to-noise ratio and low specificity of Cu 64 -DZ-l-NOTA in a PC3 subcutaneous mouse model at 4h.
- Fig. 7 B illustrates low signal-to-noise ratio and low specificity of Cu 64 -DZ-l-NOTA in a PC3 subcutaneous mouse model at 24 h.
- Fig. 7 C illustrates low signal-to-noise ratio and low specificity of Cu 64 -DZ-l-NOTA in a PC3 subcutaneous mouse model at 48 h.
- Embodiments of the present invention generally relate to conjugates of the near infrared (NIR) heptamethine carbocyanine dye (HMCD) with chelator-radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, e.g. in internal radiotherapy and/or imaging of cancer.
- NIR near infrared
- HMCD heptamethine carbocyanine dye
- chelator-radiometal complexes e.g. in internal radiotherapy and/or imaging of cancer.
- the CTC may be a chelator selected from the group comprising CB-TE2A, DiAmSar, derivatives or combinations thereof.
- Copper complexes comprising DZ-1-(L)-CTC may provide improved serum stability compared to previously known copper complexes while retaining tumor targeting and providing good imaging quality.
- the present invention also relates to methods of forming the complexes, pharmaceutical compositions comprising the complexes, methods of using the complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, soft and solid tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like.
- Advantages of the embodiments may further include improved imaging and/or tumor detection, improved therapy of tumors, cancer, metastases, and pre-cancerous lesions, improved image guided therapy, and improved penetration of tumors, especially solid tumors.
- the complexes may allow to treat aggressive tumors that have few or no treatment options, particularly small round cell tumors, including tumors such as Ewing’s sarcoma (EWS), neuroblastoma, small cell lung cancer, Merkel cell tumors, and hormone-refractory prostate cancer (HRPC).
- EWS Ewing’s sarcoma
- HRPC hormone-refractory prostate cancer
- DZ-l-(L)-CTC- 64 Cu complexes include DZ-l-CTC- 64 Cu and DZ-l-L-CTC- 64 Cu (with or without a linker), and may be referred to herein as “conjugate complexes”, “dye complexes”, “dye-chelator complexes”, “HMCD-chelator complexes”, “DZ-1 -chelator complexes”, “radiometal complexes”, “64-Cu complexes”, “ 64 Cu complexes” or simply “complexes”.
- the DZ-1 -cross-bridged tetraamine cyclam (CTC)- 64 Cu-complexes as described herein may have a higher stability in serum, e.g. as compared to a DZ1-DOTA- 64 CU complex (compare e.g. example 4).
- DZ1-CTC- 64 CU complexes may be suitable for treatment of various tumors including in particular various aggressive and difficult to treat tumors that currently lack adequate treatment options, such as Ewing’s Sarcoma (EWS) and other small cell round tumors.
- EWS Ewing’s Sarcoma
- Copper-64 ( 64 Cu) is a positron emitter thus allowing use in PET imaging which can give real time images of physiological processes in the body in vivo thus allowing accurate monitoring, e.g. of drug distribution and biokinetics simultaneously.
- Radiotherapy of cancer cells using 64 Cu which is a beta emitter may have the advantage of providing a beneficial ratio of substantial damage to the target cells while not harming non target tissues, due to its limited range of radiation. This however requires highly stable complexes, which limit the cytotoxic effects of the radioactive 64 Cu to its target.
- the stability of the 64 Cu complexes may depend on the chelator it is complexed to, and in turn the delivery ligand that the chelator is bound to, the linker used, as well as the combination of these, their size, and the type and location of tumors.
- the complexes provide cancer radiotherapy, radioimaging of cancer, or both.
- these complexes are believed to be sufficiently effective in tumor targeting, tumor shrinking and/or cancer cell killing, thus allowing a true theranostic approach with a single (rather than a pair) of therapeutics providing both diagnostic and therapy, which due to radioimaging such as PET has a high sensitivity.
- the dye’s fluorescence may be used for parallel fluorescent monitoring.
- CTC cross-bridged tetraamine cyclam
- the present invention also relates to methods of making the conjugates and complexes, pharmaceutical compositions including the complexes, methods of using the conjugates, complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like.
- the present disclosure includes compositions used in and methods relating to non- invasive imaging, in particular PET or SPECT imaging, of the complexes in vivo.
- the complexes may be used for radio therapy of cancer cells and tissues, including of solid tumors.
- the chelator conjugated to DZ-1 is a cross-bridged tetraamine cyclam (CTC), including CB-TE2A and DiAmSar, or derivatives thereof.
- CTC cross-bridged tetraamine cyclam
- cyclams, and in particular, cross-bridged cyclams when in form of the conjugate, may contribute to the better stability of the resulting complexes with 64 Cu.
- the improvement in stability e.g. in serum does not appear to be shared by conjugates to non-cross- bridged cyclen chelators such as e.g. DOTA.
- CB-TE2A is a macrocyclic chelator also known as 1,4,8,11- Tetraazabicyclo[6.6.2]hexadecane-4,ll-diacetic acid and has the chemical formula C 16 H 30 N 4 O 4 4HC1 (CAS #313229-90-2).
- DiAmSar is a macrocyclic chelator also known as 1,8-Diamino-3,6,10,13,16,19- hexaazabicyclo[6,6,6]-eicosane and has the chemical formula C I4 H 34 N 8 5H 2 0 (CAS # 91002- 72-1).
- the chelator may be conjugated with DZ-1 directly via its terminal COOH residue, or via a suitable linker, for example a lysine residue.
- suitable linkers may include alkyl linkers, e.g., without limitation, C2 to C15, e.g. C2, C3, C4, C5 or longer linkers, and polyethylene glycol linkers of varied chain length, e.g.
- linkers may include aminoacids or peptides, e.g. peptides of one or more aminoacids, e.g. up to 2, 3, 4, 5 or more amino acids linked together. Aminoacids used either as the linker or as one or more of its component in a peptide.
- Such amino acids may be selected from one or more of alanine (ala), arginine (arg), asparagine (asn), aspartic acid (asp), cysteine (cys), glutamine (gin), glutamic acid (glu), glycine (gly), histidine (his), isoleucine (ile), leucine (leu), lysine (lys), methionine (met), phenylalanine (phe), proline (pro), serine (ser), threonine (thr), tryptophan (trp), tyrosine (tyr), valine (val), or modifications or derivatives therof.
- Amino acids may be aliphatic (e.g.
- Preferred aminoacids may include lysine, glutamic acid, aspartic acid, cysteine
- preferred peptides may include peptides comprising one or more of lysine, glutamic acid, aspartic acid, cysteine.
- a DZ1-(L)-CTC radiometal complex which comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated, optionally via a linker as described herein, with a CTC chelator residue R, wherein R is selected from the group consisting of CB- TE2A, DiAmSar, or derivatives thereof, for radiolabelling with a 64 Cu radiometal, and the resulting complex comprising 64 Cu.
- HMCD heptamethine carbocyanine dye
- DZ-1-(L)-CTC conjugates suitable to form such complexes are shown in formula FI below: wherein L represents an optional linker comprising lysine, and R is selected from CB-TE2A and DiAmSar.
- a DZl-Lys-DiAmSar conjugate for radiolabelling with 64 Cu as shown below in formula Fill: [0060] It is believed that the complexes described herein may provide one or more advantages including formation of radiometal complexes that have a higher stability, including in serum. Further the complexes may provide an effective cancer therapy with low toxicity and good tumor penetration even of solid tumors. In particular, the complexes are believed to provide true theranostic agents that may be able to provide both a highly effective radiotherapy while providing highly sensitive imaging, thus allowing an image-guided therapy without the necessity to administer a matched theranostic pair.
- the complexes may further provide one or more of the following advantages: a more accurate quantitative analysis via PET or SPECT probe and/or optionally near infrared fluorescence (NIRF), a higher contrast between tumor and noncancerous tissues, a higher sensitivity, a better selectivity for cancer cells, in particular in vivo , a rapid steady state distribution in the body and organs including heart, liver, lungs and kidney, rapid tumor targeting, a uniform distribution in tumor tissues, a lack of persistence of radioactivity in one or more organs including kidney and/or liver.
- NIRF near infrared fluorescence
- these complexes may advantageously be more easily formed and/or at lower cost, may be easily labelled with a radiometal, may form stable complexes with one or more radiometal, may have high complex formation rates, a high radiochemical yield, a good labelling efficiency with one or more radiometal, a good solubility in aqueous solutions, a high stability in aqueous solutions, a high stability at physiological pH of about 7.4 (e.g.
- a high stability in vivo a low rate of dissociation of the radiometal from the complex, in particular in vivo , a good biodistribution, sufficient targeting of the complex to cancer tissues, fast cancer-specific targeting, sufficient targeting for tumor and/or metastases, sufficient targeting for larger tumors, a low organ accumulation (e.g. kidney, spleen, liver, heart), no or reduced radioactive exposure of tissues and organs, a rapid clearance rate from important or sensitive organs (e.g. from blood, liver, kidneys and other organs) after administration, sufficient tissue and tumor penetration, sufficient penetration of encapsulated tissues such as organs including dense tissues including tumor tissues, in particular calcified tumor tissues, improved and/or longer retention in the tumor.
- organ accumulation e.g. kidney, spleen, liver, heart
- no or reduced radioactive exposure of tissues and organs e.g. from important or sensitive organs (e.g. from blood, liver, kidneys and other organs) after administration, sufficient tissue and tumor penetration, sufficient penetration of
- Radiochemical yield for the isotopes of a specified element is the yield of a radiochemical separation expressed as a fraction or percentage of the activity originally present. Also called the recovery.
- the number of species transformed by radiation per eV of absorbed energy represented by the symbol G, the G-value. Radiochemical yield may be determined as will be apparent to a person of ordinary skill.
- BBB blood-brain-barrier
- Complexes as described herein may be able to provide higher tumor accumulation ratios and/or a fast blood clearance. Distribution in animals may show a favorable time-dependent clearance in their organs concomitant with specific accumulation in tumors (e.g. xenograft tumors in mice, see e.g. example 6).
- Complexes as described herein may be able to provide an improved percentage and/or speed of tumor uptake, e.g. as measured by % of injected dose (ID) of e.g. FI, FII or Fill (20 pg/kg) and the tumor-to-blood ratio at points in time (e.g. at 4, 8, 16 and/or 24 hours), as will be apparent to a person of ordinary skill.
- ID % of injected dose
- FI FI
- FII FII
- Fill 20 pg/kg
- the tumor-to-blood ratio at points in time e.g. at 4, 8, 16 and/or 24 hours
- Complexes as described herein may be able to provide increased dosing options and less accumulation and/or improved organ clearance from organs including one or more of kidneys, liver and heart. Organs such as the kidneys often are dose-limiting organs in radiotherapy. Absorbed doses may be measured as will be apparent to a person of ordinary skill, and may be e.g. about 15 Grays (Gy) or less, e.g. 10, 5, 2, 1 Gy or less. [0068] Complexes as described herein may be able to provide a reduced absorbed dose to organs and/or soft tissues such as kidney, spleen, liver, and/or hematological toxicity (e.g. thrombocytopenia, neutropenia).
- organs and/or soft tissues such as kidney, spleen, liver, and/or hematological toxicity (e.g. thrombocytopenia, neutropenia).
- Complexes as described herein may be able to provide improved effectiveness against cancer at lower amounts of radioactivity. For example, less than 50 pCi, e.g. less than 20, 20, 5 or 2 pCi may be needed.
- Complexes as described herein may be able to provide reduced toxicity at doses sufficient to treat cancer and/or significantly reduce tumor volume (e.g. by at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100%); thus a reduced LD50 and/or organ toxicity e.g. reduced kidney, spleen, liver, bone marrow, brain, heart or lung toxicity may be provided, and/or the complexes may allow to avoid or improve weight loss which often occurs during and after therapy.
- a reduced LD50 and/or organ toxicity e.g. reduced kidney, spleen, liver, bone marrow, brain, heart or lung toxicity
- Complexes as described herein may be able to provide reduced toxicity at doses sufficient to treat cancer and/or significantly reduce tumor volume while improving one or more of pain scores, bone pain scores, and median survival.
- Complexes as described herein may be able to provide sufficient anti-cancer/anti-tumor effects at reduced total dose, for example less than 250 kBq/kg, e.g. less than 200, 150, 50, and 25 kBq/kg.
- Complexes as described herein may be able to provide sufficient effectiveness to treat cancer and/or significantly reduce tumor volume while avoiding one or more side effects such as pain, dizziness, nausea, effects on the digestive tract, stomach pain, constipation, diarrhea, hair loss.
- EWS Ewing’s sarcoma
- EWS is an aggressive small round cell tumor of the bone and extra-osseous locations with metastases in lung, liver, brain.
- EWS is typically characterized by a signature chromosomal t(ll;22) translocation and EWS-FL1 fusion, typically affects young individuals (median age 15), and generally responds to radiation and poly chemotherapy.
- EWS is disseminated or recurrent, attempts of therapy are largely unsuccessful.
- the complexes described herein may administered to a subject diagnosed with EWS and/or presenting with one or more genetic alteration associated with EWS, for imaging, therapy, or both, including image-guided therapy.
- EWS E- twentysix
- typical genetic alterations of EWS include one of several possible reciprocal chromosomal translocations that generate the fusion between the gene encoding Ewing’s sarcoma breakpoint region 1 (EWSR1) and a gene encoding a member of the E- twentysix (ETS) family of transcription factors, other genetic alterations exist, some of which are described for illustration herein-below.
- EWSR1 Ewing’s sarcoma breakpoint region 1
- ETS E- twentysix
- the only detectable genetic event is the chromosomal translocation, with the resulting fusion protein likely responsible for transformation.
- Other mutations of other genes include, without limitation, STAG2 and TP53. While the vast majority of Ewing’s sarcomas harbor a fusion protein containing EWS, about 1% of the tumors bear chromosomal translocations that implicate FUS or TAF15 which like EWS are RNA-binding proteins that share a structure composed of an intrinsically disordered, low-complexity, prionlike SYGQ-rich N-terminal transactivation domain, followed by three arginine-and-glycine-rich (RGG) repeats of different lengths.
- RGG1 and RGG2 are separated by an RNA recognition motif consisting of 87 amino acids, and RGG2 and RGG3 by a zinc-finger domain.
- EWSR1 can partner not only with genes encoding ETS family members but also with a broad range of non-ETS genes to generate fusion proteins implicated in the pathogenesis of diverse soft-tissue tumors. These include, without limitation, EWSR1-NFATC2, EWSR1-POUF1, EWSR1-PATZ1, EWSRl-SMARCA, and EWSR1-SP3 which can give rise to rare, undifferentiated round-cell tumors either resembling Ewing’s sarcoma or considered to be Ewing’s sarcomas.
- EWSRl-non-ETS fusions give rise to well-defined entities, including, without limitation, DSRCT (EWSR1-WT1), myxoid liposarcoma (EWSR1-DDIT3), clear-cell sarcoma (EWSR1-ATF1), and extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3).
- Unrelated chromosomal translocations, which generate the non-FET-non-ETS gene fusions BCOR-CCNB329 and CIC-DETX4,30 may give rise to tumors with morphologic features resembling those of Ewing’s sarcoma.
- Ewing’s sarcoma These tumors were initially classified as Ewing’s sarcoma, but their pathogenesis and biologic properties are now believed to be clearly distinct from those of Ewing’s sarcoma.
- ETS factors may also be implicated in the development of diverse cancers, including pre-B-cell acute lymphoblastic leukemia and prostate cancer.
- FLIl has two ETS-binding domains separated by an FLIl-specific (FLS) sequence.
- FLS FLIl-specific
- the 5' ETS domain and the FLS sequence form the N-terminal transactivating domain, which is substantially less potent than the EWS N-terminal transactivating domain by which it is replaced in the fusion protein.
- FLIl FLIl-specific sequence
- the portion of FLIl containing the 3' ETS-binding domain that becomes fused to EWS may undergo a conformational change, which may allow it to activate a broader repertoire of genes than wild- type FLI.
- EWS E-twentysix
- Typical genetic alterations of EWS include several possible reciprocal chromosomal translocations that generate the fusion between the gene encoding Ewing’s sarcoma breakpoint region 1 (EWSR1) and a gene encoding a member of the E-twentysix (ETS) family of transcription factors.
- EWSR1 Ewing’s sarcoma breakpoint region 1
- ETS E-twentysix
- Other cancer types that the complexes as described herein may be used to successfully treat include other small cell round tumors, including, without limitation, neuroblastoma, in particular neuroblastoma in children, small cell lung cancer, Merkel cell tumors, in particular Merkel cell tumors of the skin, and euroendocrine differentiated HRPC (NE-HRPC).
- NE-HRPC euroendocrine differentiated HRPC
- Copper-64 ( 64 Cu) may be technically produced by several different reactions as will be apparent to a person of ordinary skill, with the most common methods using either a reactor or an accelerator. Thermal neutrons can produce 64 Cu in low specific activity (the number of decays per second per amount of substance) and low yield through the 63 Cu(n,y) 64 Cu reaction.
- 64 Cu may be produced using high-energy neutrons via the 64 Zn(n,p) 64 Cu reaction in high specific activity but low yield.
- 64 Ni(p,n) 64 Cu nuclear reaction may produce large quantities of the nuclide with high specific activity.
- radiotherapy as described herein may be improved by pairing such therapy with Positron Emission Tomography (PET) or SPECT and/or to provide image-guided therapy.
- PET Positron Emission Tomography
- the complexes as described herein may be used for imaging only, or therapy only.
- PET detects positron-emitters such as 64 Cu, and may optionally be combined with Computerized Tomography (CT) imaging, i.e. PET/CT.
- CT Computerized Tomography
- x-ray scans are taken from different angles with the various slices arranged in 3D by a computer which may be used as a map to overlay with signals detected by PET.
- radiotherapy may be performed internally, i.e. a source of radiation may be provided inside the subject’s body for cancer therapy.
- Internal radiation therapy may be performed systemically, thus the treatment travels in the blood to tissues throughout the body to kill cancer cells in a targeted fashion trough the radiation the cells in proximity to the radiometal are exposed to.
- treatment may be through systemic or localized/site-specific administration, such as oral or intravenous injection for systemic administration, or localized injection or deposits, e.g. through use of seeds in brachytherapy of accessible tumors, as will be apparent to a person of ordinary skill.
- the radiometals can be delivered to tumors and metastases in a targeted fashion.
- one or more radiometal complex may be administered in a coordinated administration protocol.
- imaging may be performed before and/or during one or more therapy time intervals to provide an image-guided therapy.
- the amount, concentration, duration and form of administration will be adjusted accordingly, as will be apparent to a person of ordinary skill.
- imaging may allow to locate a suspected tumor, e.g. after genetic testing revealed a genetic alteration and pre-disposition, e.g. for a particular type of cancer, tumor or group of tumors, such as, without limitation, EWS.
- therapy may be performed, either systemically (e.g. systemic administration such as by IV or orally), or localized administration restricted to the tumor site and its surroundings (e.g. by localized injection).
- imaging and therapy may be performed in the same step.
- imaging may be performed one or more times before and over the course of therapy to monitor tumor development and, upon therapy, shrinkage.
- the DZ-1-(L)-CTC conjugates form complexes of high thermodynamic stability and kinetic inertness with 64 Cu, and will rapidly, quantitatively and stably coordinate with the radiometal at room temperature (at about 20 DEG C, or e.g. at less than 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 DEG C), near neutral pH (at about 7, e.g. about 5 or more, about 6 or more, about 8 or less, about 7.5 or less), and at a low DZ-l-Lys-DOTA concentration, e.g. 0.1-100 micromolar or nanomolar, e.g. about 1 to about 20 micromolar, e.g. about 1 to about 10 micromolar, e.g. about 5-8 micromolar, allowing to easily provide radiopharmaceutical formulations.
- room temperature at about 20 DEG C, or e.g. at less than 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 DEG
- Complexes as described herein may provide superior imaging during detection including e.g. PET, in particular one or more of better signal-noise ratio, stronger signal, and better resolution.
- Complexes as described herein may be suitable for tumors of all sizes with effects including tumor shrinkage, and, due to increased stability, in vivo distribution and/or imaging sensitivity, may be particularly effective to detect and destroy small tumors or metastases of a volume of less than e.g. about 5 to about 0.1 cm 3 or less, e.g. about 5 cm 3 or less, about 4 cm 3 or less, about 3 cm 3 or less, about 2 cm 3 or less, about 1 cm 3 or less, about 0.5 cm 3 or less, about 0.1 cm 3 or less.
- tumor volumes apply to human patients typically having a weight of about 140 to 200 lb, e.g. about 170 lb.
- tumor volumes will be less or more depending on body weight. Advantages may include a significant reduction or removal of metastases, higher absorbed doses, and/or a lower tissue penetration range.
- Complexes as described herein, due to increased stability and/or improved tumor penetration, may be particularly effective to also destroy larger tumors, in particular solid tumors, of a volume of more than e.g. about 5 cm 3 , e.g. about 5 cm 3 to about 2000 cm 3 or more, e.g. about 50, 100, 200, 500 or 1000 cm 3 or more.
- Complexes as described herein may be suitable for tumors of all sizes with effects including tumor shrinkage. Advantages may include a significant reduction or removal of metastases, higher absorbed doses, and/or a lower tissue penetration range.
- Positron Emission Tomography may be used to provide data on radiometal distribution within target tissues by detection of gamma photons resulting from the decay of the radiometals.
- PET Positron Emission Tomography
- High spatial resolution of commonly available PET scanners allows to visually map radiometal decay events and thus provide an image which reflects the distribution of a radiometal in the body after administration of a radiometal complex.
- Such images provide anatomic and functional information to aid medical diagnosis and assist to track progress and allow adjustment of radiotherapy.
- cancer as referred to herein includes precancerous and cancerous cells or tissues, tumors and their metastases, primary and secondary tumors.
- the conjugates and methods described herein may be particularly advantageous for use in brain cancers, brain tumors and their metastases.
- CB-TE2A, DiAmSar, or derivatives thereof, in combination with DZ1 and 64 Cu as described, and in particular when conjugated via a lysine linker allows the radioactive conjugates to pass across the blood-brain barrier and allow imaging and therapy throughout the brain, including tumors located deep within the brain structure that often are not or not efficiently accessible by other methods and may be inoperable.
- the cancer treated by the complexes may be selected from the group comprising: brain cancer, prostate cancer, lung cancer, Non-small-cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), pancreatic cancer, kidney cancer, lymphoma, colorectal cancer, skin cancer, HCC cancer, and breast cancer, squamous-cell carcinoma of the lung, anal cancers, epithelial tumors of the head and neck, bone cancer, carcinoma of the cervix, skin cancer, melanoma, hematopoietic cancers, lymphoma, and myeloma, or metastases of any thereof, including e.g., without limitation, metastases occurring in the brain, the bone, or other organs, brain tumors or their metastases, brain tumors and their brain, bone, lung or other organ metastases, bone tumors or their brain, bone, lung or other metastases, prostate tumors or their brain, bone, lung or other metastases, prostate tumors or their brain, bone, lung or other met
- the cancer may be a central nervous system (CNS) or brain tumor, or metastasis thereof, selected from the group comprising: acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, glioma, glioblastoma, medulloblastoma, meningioma, oligodendroglioma, pituitary tumors, primitive neuroectodermal tumor, Schwannoma, brain stem glioma, ependymoma, juvenile pilocytic astrocytoma, optic nerve glioma, pineal tumor, rhabdoid tumor, adult Low-Grade (WHO Grade I or II) Glioma/Pilocytic, Infiltrative Supratentorial Oligodendroglioma, Anaplastic Gliomas/Glioblastoma, Adult Intracranial Ependym
- CNS central nervous system
- the cancer may be a Non-small-cell lung carcinoma selected from a Squamous-cell carcinoma, Adenocarcinoma (Mucinous cystadenocarcinoma), Large-cell lung carcinoma, Rhabdoid carcinoma, Sarcomatoid carcinoma, Carcinoid, Salivary gland-like carcinoma, Adenosquamous carcinoma, Papillary adenocarcinoma, and Giant-cell carcinoma.
- the cancer may be a small-cell lung carcinoma, including a Combined small-cell carcinoma.
- the cancer may be a non-carcinoma of the lung, including a Sarcoma, Lymphoma, Immature teratoma, and Melanoma.
- a pharmaceutical composition comprising a radiometal complex, or for forming such complexes.
- the pharmaceutical composition may be for human or for veterinary use, and comprise one or more conjugate or complex of the invention (or a salt, solvate, metabolite, or derivative thereof) with one or more pharmaceutically acceptable carrier and/or one or more excipient and/or one or more active.
- the one or more carrier, excipient and/or active may be selected for compatibility with the other ingredients of the formulation and not unduly deleterious to the recipient thereof.
- Such carriers are known in the art and may be selected as will be apparent to a person of ordinary skill in the art.
- routes of administration for the compounds and pharmaceutical compositions include, but are not limited to: oral (e.g. in pill form), intravenous (i.e. injected into a subject’s vein), interstitially (i.e. inserted into a space in the body), intraperitoneal, subcutaneous, or intramuscular, and/or by brachytherapy (insertion of radioactive implants or seeds directly into the affected tissue, e.g. into or near a tumor location). Administration may be systemic (e.g. via blood circulation) or regional (e.g. localized to a particular organ of the body or part thereof).
- the pharmaceutical compositions of the invention contain a pharmaceutically acceptable excipient suitable for rendering the compound or mixture administrable via the above routes of administration.
- the active ingredients can be admixed or compounded with a conventional, pharmaceutically acceptable excipient or carrier.
- a mode of administration, vehicle, excipient or carrier should generally be substantially inert with respect to the active agent, as will be understood by those of ordinary skill in the art. Illustrative of such methods, vehicles, excipients, and carriers are those described, for example, in Remington: The Science and Practice of Pharmacy (2020), ISBN-10: 0128200073, or in Handbook of Pharmaceutical Excipients, Ninth edition (2020), ISBN-10: 0857113755, the disclosures of which is incorporated herein by reference.
- the excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- the pharmaceutical formulations may be conveniently made available in a unit dosage form by any of the methods generally known in the pharmaceutical arts. Generally speaking, such methods of preparation comprise presenting the formulation in a suitable form for delivery, e.g., forming an aqueous suspension.
- the dosage form may optionally comprise one or more adjuvant or accessory pharmaceutical ingredient for use in the formulation, such as mixtures, buffers, and solubility enhancers.
- parenteral dosage forms (i.e. that bypass the GI tract) of the pharmaceutical formulations include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions.
- controlled-release parenteral dosage forms can be prepared for administration of a patient, including, but not limited to, administration DUROS®-type dosage forms, and dose-dumping.
- suitable vehicles that can be used to provide parenteral dosage forms of the compounds of the invention include, without limitation: sterile water; water for injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to, sodium chloride injection, Ringer's injection, dextrose Injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
- Compounds that alter or modify the solubility of a pharmaceutically acceptable salt of a compound of the invention as disclosed herein can also be incorporated into the parenteral dosage forms of the disclosure, including conventional and controlled-release parenteral dosage forms.
- formulations for parenteral administration include aqueous and non- aqueous sterile injection solutions, which may further contain additional agents, such as anti oxidants, buffers, bacteriostats, and solutes, which render the formulations isotonic with the blood of the intended recipient.
- the formulations may include aqueous and non-aqueous sterile suspensions, which contain suspending agents and thickening agents.
- injectable preparations for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation can also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- forms suitable for oral administration include tablets, troches, capsules, elixirs, suspensions, syrups, wafers, or the like prepared by art recognized procedures.
- the amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained.
- a syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier, for example, ethanol, glycerine or water, with a flavoring or coloring agent.
- solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcelhdose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h)
- solid compositions of a similar type can be employed as fillers in soft and hardfilled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- embedding compositions that can be used include polymeric substances and waxes.
- Solid compositions of a similar type can also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
- the active compounds conjugates or complexes can be in micro- encapsulated form with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active compound can be admixed with at least one inert diluent such as sucrose, lactose and starch.
- Such dosage forms can also comprise, as in normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose.
- the dosage forms can also comprise buffering agents. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- buffering agents can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- the active compounds, conjugates or complexes can be present in form of salts, which may be particularly suitable for use in the treatment of cancer.
- the salts of the present invention may be administered to the patient in a variety of forms, depending on the route of administration, the salt involved, and the cancer being treated.
- an aqueous composition or suspension of the salts may be administered by injection, or in the form of a pharmaceutical matrix by injection or surgical implantation, at a desired site.
- the particular technique employed for administering the matrix may depend, for example, on the shape and dimensions of the involved matrix.
- the salt is introduced substantially homogeneously in a tumor to minimize the occurrence in the tumor of cold (untreated) areas.
- the salt is administered in combination with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier refers to an excipient that can be included in the compositions of the invention and that causes no significant adverse toxicological effects to the patient.
- a wide variety of pharmaceutically acceptable carriers or excipients are available and can be combined with the present salts, as will be apparent to one of ordinary skill in the art.
- effective amounts, toxicity, and therapeutic efficacy of the active compounds conjugates or complexes can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dosage can vary depending upon the dosage form employed and the route of administration utilized.
- the dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50.
- compositions and methods exhibit large therapeutic indices.
- a therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the compound of the invention, which achieves a half- maximal inhibition of symptoms) as determined in cell culture, or in an appropriate animal model.
- IC50 i.e., the concentration of the compound of the invention, which achieves a half- maximal inhibition of symptoms
- Levels in plasma can be measured, for example, by high performance liquid chromatography.
- the effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
- the dosage of a pharmaceutical formulation as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen.
- the dosing schedule/regimen can vary, e.g. once a week, daily, or in particular predetermined intervals, depending on a number of clinical factors, such as the subject's sensitivity to each of the active compounds.
- an effective dose of a composition comprising radiometal complex can be administered to a patient once.
- an effective dose of a composition comprising a radiometal complex can be administered to a patient repeatedly.
- the radiometal complex can be administered over a period of time, such as over a 5 to 60 minute period, e.g. about 30 minutes.
- the administration can be repeated, for example, on a regular basis, such as hourly, daily, bi-weekly or weekly, e.g. in a suitable time interval of e.g. about 6, 12, 24, 48 or 72 hours.
- the treatments can be administered on a less frequent basis. For example, after an initial administration, administration can be repeated once per week, month, six months or a year or longer.
- the amount of the active compound, conjugate or complex in the pharmaceutical composition can be based on weight, moles, or volume.
- the pharmaceutical composition comprises at least 0.0001%, 0.1%, 0.5% 1%, 2%, 3%, 4%, 5% or 10% of the active.
- the pharmaceutical composition comprises 0.01%- 99% of the active, e.g. 0.05%-90%, 0.1%-85%, 0.5%-80%, l%-75%, 2%-70%, 3%-65%, 4%- 60% or 5%-50% of the active.
- the dosage of a composition as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen.
- the dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the compound of the invention.
- the method may comprise providing a radiometal complex; administering the complex to a subject; and optionally performing imaging, e.g. PET imaging, to detect the emitter released.
- imaging may be performed, for example, about 6 to 48 hours post administration. Imaging may be performed in comparison to normal tissue/cells to determine uptake rates differing in cancer/tumor tissues versus normal tissues.
- in situ pharmacokinetic and pharmacodynamic analyses in a tumor or normal cell or tissue may be performed.
- the method can comprise providing the complex; contacting it with the cancer cells, tumor, or normal cell or tissue; and imaging the cancer cells, tumor, or normal cell or tissue, followed by pharmacokinetic and/or pharmacodynamics analyses, e.g. determining the signal (including radioactivity and/or NIR fluorescence, and changes thereof, at one or more point of time over time, e.g. before and after administration, and one or more times after administration.
- kits for providing or making a radiopharmaceutical preparation comprising a radiometal complex are provided.
- a vial containing the nonradiometal components of a radiopharmaceutical preparation usually in the form of a sterilized, validated product to which the appropriate radiometal is added or in which the appropriate radiometal is diluted before use.
- One or more kit component may be provided in form of an optionally buffered solution, or may be provided for dissolution in an optionally buffered solution.
- the kit may be a single or multidose vial, and the radiopharmaceutical preparation may require additional steps, e.g., without limitation, boiling, heating, filtration and/or buffering.
- Radiopharmaceutical preparations derived from kits generally are intended for immediate use after preparation, e.g. within 6-24 hours, e.g. within about 12 hours of preparation.
- the kit can also further comprise conventional kit components, such as needles for use in injecting the compositions, one or more vials for mixing the composition components, and the like, as are apparent to those of ordinary skill.
- kit components such as needles for use in injecting the compositions, one or more vials for mixing the composition components, and the like, as are apparent to those of ordinary skill.
- instructions either as inserts or as labels, indicating quantities of the components, guidelines for mixing the components, and protocols for administration, can be included in the kits.
- the concentration of the complexes employed in the pharmaceutical compositions and/or the amount administered to a patient or subject may vary and depends upon a variety of factors including, for example, the particular complex and/or pharmaceutically acceptable carrier employed, the particular disease being treated, the extent of the disease, the size and weight of the patient, and the like.
- the complex may be employed in the pharmaceutical compositions, and the compositions may be administered to a patient to provide initially lower levels of radiation dosages which may be increased until the desired therapeutic effect is achieved.
- the complexes may be employed in pharmaceutical compositions which comprise an aqueous carrier to provide a concentration of absolute radioactivity which may range from about 4 MBq per milliliter (ml) (about 0.1 mCi/ml) or less to about 370 MBq/ml (about 10 mCi/ml), and all combinations and subcombinations of ranges therein.
- the concentration of the complex in the pharmaceutical compositions may be from about 37 MBq/ml (about 1 mCi/ml) to about 370 MBq/ml (about 10 mCi/ml).
- compositions may be administered to a patient to provide a radiation dose which may range from about 1 KSv (about 1x105 Rem) to about 74 KSv (about 7.4 MRem), and all combinations and subcombinations of ranges therein.
- the compositions may be administered to a patient to provide a radiation dose of from about 7.4 KSv (about 7.4x105 Rem) to about 74 KSv (about 7.4 MRem).
- Such amounts are referred to herein as effective amounts or therapeutically effective amounts.
- the pharmaceutically acceptable carrier may further comprise a thickening agent.
- Thickening agent refers to any of a variety of generally hydrophilic materials which, when incorporated in the present compositions, may act as viscosity modifying agents, emulsifying and/or solubilizing agents, suspending agents, and/or tonicity raising agents.
- Thickening agents which may be suitable for use in the present radiopharmaceutical compositions include, for example, gelatins, starches, gums, pectin, casein and phycocolloids, including carrageenan, algin and agar, semi -synthetic cellulose derivatives, polyvinyl alcohol and carboxyvinylates, and bentonite, silicates and colloidal silica. Other thickening agents would be apparent to one of ordinary skill.
- the concentration of thickening agent may range from about 0.1 to about 500 milligrams (mg) per ml of pharmaceutical composition.
- the concentration of thickening agent may be from about 1 to about 400 mg/ml, e.g. from about 5 to about 300 mg/ml, e.g. from about 10 to about 200 mg/ml, e.g. from about 20 to about 100 mg/ml, or e.g. from about 25 to about 50 mg/ml.
- Compositions which may be prepared from the complexes, pharmaceutically acceptable carriers and optional thickening agents include, for example, suspensions, emulsions, and dispersions.
- the complexes can be formulated and administered to a patient as a suspension.
- Suspension may refer to a mixture, dispersion or emulsion of finely divided colloidal particles in a liquid. Suspensions may be obtained, for example, by combining the complexes with an inert solid support material.
- Particulate support materials which may be suitable for use as an inert solid support in the compositions of the present invention include, for example, materials derived from carbon, including those forms of carbon typically referred to as carbon black (lampblack) and/or activated carbon, as well as finely powdered oxides, Kieselguhr, and diatomaceous earth.
- the support material comprises carbon black or activated carbon.
- the size of the particles of the particulate support material may vary and depends, for example, on the particular support material, complex, thickening agent, and the like, employed and may comprise particles ranging in size, for example, from about 0.1 micrometer (mm) to about 50 mm, e.g. the particle size may be from about 0.5 to about 25 mm, e.g. from about 1 to about 10 mm, e.g. from about 2 to about 5 mm.
- Delivery of a therapeutically effective activity of a complex can be obtained via administration of a pharmaceutical composition comprising a therapeutically effective activity or dose of the complex, i.e. in a concentration that is sufficient to elicit the desired therapeutic or imaging effect according to the methods described herein.
- a therapeutically effective activity may be an activity effective to treat cancer, such as inhibiting or slowing growth of cancerous or precancerous tissue, or lowering the survival rate of cancer or pre-cancerous cells.
- the therapeutically effective dosage will vary somewhat patient to patient, and will depend upon the condition of the patient and the route of delivery. The effective activity of any particular compound would be expected to vary according to the weight, sex, age, and medical history of the subject.
- the effective dose can include, but are not limited to, the severity of the patient's condition, the disease or disorder being treated, the stability of the complex, and, if appropriate, any additional antineoplastic therapeutic agent being administered with the complex. Methods to determine efficacy and dosage are known to those of ordinary skill.
- RP reversed-phase
- HPLC high-performance liquid chromatography
- the mobile phase may change from 60% solvent A (e.g. 0.1% trifluoroacetic acid in 80% water) and 40% solvent B (e.g. 0.1% trifluoroacetic acid in 80% aqueous acetonitrile) to 100% solvent B over a period of e.g. about 30 min at a flow rate of about 1 ml/min monitoring at e.g. about 254 and/or about 780 nm).
- Electrospray Ionization Mass Spectrometry (ESI-MS) analysis may be performed on the synthesized compounds, e.g. on a Thermo TSQ Fortis Triple Quadrupole mass spectrometer system.
- DZ-1 may be synthesized e.g. as described below, then it may be conjugated directly to a CTC, or alternatively, a linker may be used to link DZ-1 with a CTC, e.g. a lysine linker, e.g. as shown in scheme 2 herein-below, e.g. to form DZ-l-Lys-CB-TE2A, as shown e.g. in scheme 3 herein-below, or DZl-Lys may be linked to another CTC, e.g. without limitation, DZ-l-Lys- DiAmSar (not shown).
- a linker may be used to link DZ-1 with a CTC, e.g. a lysine linker, e.g. as shown in scheme 2 herein-below, e.g. to form DZ-l-Lys-CB-TE2A, as shown e.g. in scheme 3 herein-below, or DZ
- DZ-1 may be directly linked to a CTC.
- the resulting DZ-1-(L)-CTC conjugate, with or without linker L, may then be subjected to 64 Cu radiolabeling (shown herein-below in schemes 4 and 6, respectively).
- Scheme 1 shown below illustrates the first steps of conjugate synthesis forming a DZ-1- (L)-CTC conjugate, showing synthesis of dye compound 4, also referred to herein as “DZ-1”; alternative routes of synthesis will be apparent to a person of ordinary skill.
- the resulting dark red solid may be dissolved in 50 ml of methanol. Ethyl ether 150 ml may be added. The precipitate may be filtered and washed a sufficient number of times and volume e.g. with ether (e.g. 15 ml, three times) followed by a sufficient number of volume and times washing with acetone (e.g. 15 ml, three times). The product obtained is a white solid (2.7 g, 58%).
- DZ-l-Lysine (compare scheme 2 above): DZ-1 4 (200 mg, 0.28 mmol) may be dissolved in 5 ml anhydrous CH2CI2. Ethyl chloroformate (CICOOC2H5) (46 mg, 0.42 mmol) and triethylamine (57 mg, 0.57 mmol) may be added. The mixture may be stirred for sufficient duration, e.g. about 2 hours, then N-a-Boc-Lysine 5 (70 mg, 0.28 mmol) in a sufficient volume, e.g. 2 ml of Dimethylformamide (DMF), may be added, and stirred for an additional sufficient duration, e.g.
- DMF Dimethylformamide
- DZ-1-(N- a-Boc)-Lysine may be dissolved in TFA (95%) 5 ml and the mixture may be sufficiently stirred, e.g. about 3 h at ambient temperature, e.g. at RT (about 20 degree centigrade).
- a sufficient amount of ethyl ether, e.g. 40 ml, may be added.
- the suspension may be centrifuged for sufficient time to achieve separation, allowing to decant the ether.
- the product may be dried, e.g. by placing it under high vacuum for sufficient duration, e.g. overnight.
- the resulting product 6 may be used without further purification for the steps described below.
- a CTC here CB-TE2A in a suitable form, e.g. one of its salt, e.g. a HC1 salt, may be mixed with suitable amounts of diisopropylcarbodiimide (DIC) and diisopropylethylamine (DIEA), or alternatively to DIEA, of Et3N.
- DIC diisopropylcarbodiimide
- DIEA diisopropylethylamine
- CB-TE2A * 4HC1 salt 7 (50 mg, 0.11 mmol), diisopropylcarbodiimide (DIC) (14 mg, 0.11 mmol), and diisopropylethylamine (DIEA) (14 mg, 0.11 mmol) may be dissolved in a suitable volume of DMF, e.g. 2 ml Dimethylformamide (DMF).
- DMF Dimethylformamide
- the mixture may be stirred for a suitable time to ensure complete solution and/or mixing, e.g. about 30 min.
- DZ-l-L (a conjugate with terminal aminocarboxyl functionality), e.g.
- DZ-l-Lysine 6 (92 mg, 0.11 mmol) may be added, and stirred for a suitable time to allow for complete reaction, e.g. about 5 hours at room temperature (RT), e.g. about 20 DEG C.
- the product is precipitated, e.g. in a suitable volume of cold diethyl ether (e.g. about 40 ml). Centrifugation for sufficient time and rpm separates the precipitated product, e.g. for about 5 min at about 3500 rpm.
- the crude product may be purified by a suitable method, e.g. by C18-RP semi-preparative, to afford the DZ1-L-CTC, here DZ-l-Lysine-CB-TE2A 8, as a dark green solid.
- Radioactive labelling and preparation of a 64 Cu-DZ-l-L-CTC here 64 Cu-DZ-l- lysine-CB-TE2A (compare scheme 4):
- a reaction vial of suitable volume e.g. 1.5 ml
- the following may be added: about 5 pg of the DZ1-L-CTC, here the DZ-l-Lysine-CB-TE2A 8 in about 200 m ⁇ of 0.1 M MEOAc (pH about 5.5) solution, about 2 ⁇ 3 mCi of 64 CuCl2 in 0.1 M HC1.
- the reaction mixture may be carefully mixed, e.g.
- the 64 Cu-DZ-l-lysine-CB-TE2A 9 complex may then be purified by a suitable method, e.g. by reversed-phase HPLC with a suitable column, e.g. an Apollo C18 RP column (5 m, 250 xlO mm).
- the column eluate may monitored by a suitable method, e.g. by ultraviolet absorbance at a suitable wavelength, e.g. about 254 nm, and/or with a Nal crystal detector.
- the mobile phase may change from 40% solvent A (e.g.
- DZ-l-DiAmSar (compare scheme 5): A mixture of suitable amounts of DZ-1 4 (e.g. about 50 mg, 0.071mmol), diisopropylcarbodiimide (DIC) (e.g. about 13.5 mg, 0.11 mmol) and hydroxybenzotriazole (HOBt) (e.g. about 11.5 mg, 0.085 mmol) may be dissolved in a suitable amount of DMF, e.g. about 2 ml DMF. The mixture is stirred for a suitable time to allow complete solution and mixing, e.g.
- a CTC here DiAmSar » 5H20 10 (29 mg, 0.071 mmol) may be added and stirred for a suitable amount of time to allow for reaction, e.g. about 5 hours at RT.
- the product may be precipitated in a suitable volume of medium and at a suitably cold temperature to allow for precipitation, e.g. cold diethyl ether (e.g. about 40 ml).
- the precipitate is separated e.g. by centrifugation at a suitably high rpm for a suitable time, e.g. for about 5 min at about 3500 rpm.
- the precipitated crude product may be purified by a suitable method, e.g.
- the 64 Cu-DZ-l-DiAmSar 12 complex may be purified by a suitable method, e.g. by Reversed-phase HPLC with a suitable column, e.g. an Apollo C18 RP column (5 m, 250 xlO mm).
- the column eluate may monitored by a suitable method, e.g. by ultraviolet absorbance at a suitable wavelength, e.g. about 254 nm, and/or with a Nal crystal detector.
- the mobile phase may change from 40% solvent A (e.g. about 0.1% trifluoroacetic acid in about 80% water) and 60% solvent B (e.g.
- a suitably radioactive amount and MBq/pg ratio of radiometal may be added to the DZ-1-(L)-CTC conjugates, as will be apparent to a person of ordinary skill.
- the ratio may be up to about 200 MBq/pg (radiometal xonjugate), about 4 to about 100 MBq/pg or about 8 to about 50 MBq/pg e.g. about 20 MBq/pg.
- 100 MBq (2.7 mCi) of 64 Cu to 5 pg of DZ-l-CTC may be added to 0.1N ammonium acetate (pH 5.5) buffer, and the mixture may be incubated at a suitable temperature for a sufficient time to achieve complete labelling, for example at about 20°C to about 60°C, or about 30°C to about 50°C, e.g. at about 40°C for about 10 to about 60 minutes or about 20 to about 40 minutes, e.g. about 30 minutes.
- radiolabeling may be accomplished by addition of about 100 MBq (2.7 mCi) of 64 Cu to 5 pg of DZ-1-(L)-CTC in 0.1N ammonium acetate (pH 5.5) buffer, and incubating the mixture at about 40°C for about 30 min.
- the resulting 64 Cu complex may be purified by Reversed-phase HPLC with an Apollo C18 RP column (5 p, 250 xlO mm). The column eluate may be monitored by ultraviolet absorbance at 254 nm and with a Nal crystal detector.
- the mobile phase may change from 40% solvent A (0.1% trifluoroacetic acid in 80% water) and 60% solvent B (0.1% trifluoroacetic acid in 80% aqueous acetonitrile) to 100% solvent B at 30 min at a flow rate of 3 ml/min.
- the pure fraction of the complex from the HPLC may be concentrated by gently blowing a positive flow of nitrogen for drying.
- the residue left in test tube upon concentration may be reconstituted in a suitable buffer depending on further testing or administration, e.g. IX PBS buffer (1.0 ml).
- the serum stability of the complexes described herein may be determined as follows.
- a suitable amount e.g. 50 microcuries of a DZ-l-(L)-CTC- 64 Cu complex as described herein, e.g.
- DZ-l-Lysine-CB-TE2A, DZ-l-Lysine-DiAmSar, DZ-1-CB-TE2A, DZ- 1-DiAmSar may be added into a suitable volume, e.g. 100 m ⁇ , of fetal bovine serum (Invitrogen, Grand Island, NY). After incubation at 37°C for suitable time intervals, e.g. 1, 3, and 6 h, aliquots of the mixture may be removed and filtered, e.g. through a 0.2 mM microspin filter. The resulting filtrates may be analyzed by a suitable separation and detection method, e.g.
- DZ-l-Lysine-DOTA- 64 Cu lacks stability in serum. Due to lesser dissociated 64 Cu, the DZ1-(L)-CTC may provide clearer imaging and tumor detection in organs, and a better signal -to-noise ratio. Therapy may be more effective and have lesser side effects.
- Example 5 In vivo stability and protein assays to detect undesirable 64 Cu binding
- a gel electrophoresis assay may be performed to detect separate and detect radionuclide-emitting SOD or any other protein, as will be apparent to a person of ordinary skill.
- the 64 Cu may bind to other proteins, including e.g., without limitation, superoxide dismutase (SOD) in liver, and any assay that allows separating protein-bound 64 Cu from complex/conjugate-bound 64 Cu and measuring the radionuclide-emission of the protein- bound 64 Cu may thus be used to determine a lack of stability and undesirable binding to proteins present in the organs of the body (liver, kidney, etc.). If excessive radiation is determined in particular non-tumorous organs, this may also indicate dissociation and a lack of stability. Similarly, organ-specific assays may be performed, e.g. on mouse or rat liver, kidney etc..
- SOD superoxide dismutase
- Example 6 PET/microPET imaging of mice with DZ-l-(L)-CTC- 64 Cu complexes to determine blood clearance and organ distribution.
- the specificity and tumors tissue penetration of the dye-CTC complexes described herein may be determined by any suitable conventional method, including e.g. PET/CT imaging, e.g. using a suitable animal model, as will be apparent to a person of ordinary skill.
- a mammalian model such as a mouse model, in particular, a xenograft mammalian model having the cancer of interest, may be used for testing of the conjugates by imaging, in particular, PET imaging.
- Other mammalian models may be used, as will be apparent to a person of ordinary skill (e.g. rat, rabbit, dog, monkey, etc.).
- MicroPET imaging i.e. PET performed on small animals
- PET or microPET
- PET may be performed for imaging and/or therapy or both, to provide image guided therapy.
- Doses may be adjusted for imaging/therapy, or one dose may be suitable for both imaging and therapy.
- the DZ-l-(L)-CTC- 64 Cu complex may be administered intravenously to individual animals, e.g. mice, e.g. in a suitable number, e.g. a set of five, by injecting a suitable amount, e.g. about 300-500 pCi of the complex.
- the Transaxial microPET images may be collected in suitable intervals, e.g. hourly, e.g.
- the standardized uptake value (SUV) analyses may be performed as will be apparent to a person of ordinary skill, here on on cancer xenografts and muscles of individual mice as defined by CT scans and a tumor-to- muscle ratio may be calculated for each group at these time points, as will be apparent to a person of ordinary skill.
- Blood clearance and organ distribution may be determined as follows. After anesthesia (e.g. by isoflurane 2- 3%), a group of mice, e.g. 5 mice, may be injected with one or more 64 Cu radiolabeled DZ1-(L)- CTC, e.g. DZ-l-Lysine-CB-TE2A or DZ-l-DiAmSar (e.g. about ⁇ 5 pCi), e.g. via the tail vein.
- Retro-orbital blood samples e.g. 25 pi
- a gamma counter e.g. 1480 WizardTM, Perkin-ElmerTM
- Mice may be sacrificed immediately after the last blood sampling.
- Tumors and organs including but not limited to e.g. heart, liver, lung, kidney, small intestine, stomach, bone, bone marrow, muscle, spleen, skin and brain
- Organ distribution data in duplicate may be obtained for each 64 Cu complex in mice at multiple time points in suitable time intervals, e.g. at three time points, e.g. at lh, 2h and 3h. Such determination may show a favorable blood and organ clearance for DZ1-(L)-CTC- 64 Cu. A comparison of these complexes to other less stable complexes, in particular e.g. to DZ-1- Lys-DOTA- 64 complexes, may show superior clearance.
- Image registration and analysis may be performed as follows.
- PET/CT images may be processed following a standard protocol as will be apparent to a person of ordinary skill, e.g. using standard software as per the manufacturer’s guides, e.g. using the ASIProTM software, Siemens HealthineersTM, Er Weg, Germany.
- Pixel-wise standardized uptake values (SUVs) of PET may be calculated as a product of the pixel -wise activity divided by the injected dose and body weight.
- the tumor target may be delineated as 40% of maximum of SUV, anatomically overlaying with a CT image through image registration through the software used.
- DZ-l-Lysine-DOTA also compare example 4
- 64 Cu radiolabeled DZ1-(L)-CTC complexes as described herein are more stable compared to e.g. DZ-l-Lysine-DOTA, also compare example 4, and thus can provide a higher in vivo stability compared to e.g. DZl-Lys-DOTA- 64 Cu, and/or increased specifity, which may be shown by PET imaging, e.g. the Standardized uptake values (SUV) in the tumor may be improved, tumor retention and/or tumor penetration may be increased e.g. as shown by PET/CT.
- DZ1-(L)-CTC- 64 CU may also advantageously provide a more rapid distribution and clearance that allows improved imaging and therapy and lower side effects.
- the distribution ratio between tumor and skeletal muscle and thus specificity may be determined by PET as described above and, for example, the tumor-to-muscle ratio after about 24 h of administration may be about 8 : 1 and may be significantly increased by about 20% or more (10:1), about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 100% or more, about 120% or more (20:1), after about 36 to about 48 h of administration, or longer, as the tumor tissue retains the conjugate for an extended time, and such ratio may exceed that of DZ-l-Lysine-DOTA.
- Example 7 DZ1-(L)-CTC- 64 CU image-guided radiotherapy/PET, tumor weight reduction and retained body weight in mice, EWS
- Ewing sarcoma (EWS) cell lines and in vivo models may be used to test efficacy against EWS, in particular against disseminated or recurrent EWS.
- nude mice may be inoculated subcutaneously with human EWS cancer cells (e.g. ATCC® CRL-2971TM, publicly available e.g. from ATCC).
- the base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001.
- fetal bovine serum ATCC 30-2020
- ATCC® CRL-2971TM is a human clear cell sarcoma cell line with an EWS/ATF1 fusion gene produced by a consistent t(12;22)(ql3;ql2) chromosomal translocation.
- tumor-bearing mice will be administered intravenously (e.g. via the tail vein) with a suitable amount and volume for a suitable duration, e.g. about 0.2 ml of a DZ1-(L)-CTC- 64 CU (e.g. about 5.55 GBq/kg).
- the treatment may be given in regular intervals, e.g. once a day or week for several days or weeks, e.g. once a week for 4 weeks.
- a control group may be injected via tail vein with vehicle solvent (e.g. saline of the same volume, e.g. about 0.2 ml). After the treatment, mice may be kept for another period, e.g. about 12 weeks. Endpoint of the study will be differential tumor growth between treatment and control group. Body weight may be monitored throughout.
- vehicle solvent e.g. saline of the same volume, e.g. about 0.2 ml
- DZ1-(L)-CTC- 64 CU may be determined essentially using nude mice as described above except that inoculating with human cancer cells is performed intracranially, to determine crossing of the blood-brain-barrier, and the endpoint of the study will be differential animal death between treatment and control group. Body weight may be monitored throughout.
- Tumor specific targeting may be determined with one or more methods, e.g. 1) near infrared fluorescence tumor imaging to detect accumulation of the DZ-1 moiety in the tumor, 2) SPECT/CT nuclear imaging in the same tumor, and/or 3) PET imaging (also see PET described herein-above). PET and SPECT imaging may determine higher clearance and a better signal-to- noise ratio, and allow for image-guided therapy.
- Mice may be euthanized when the tumor size exceeded the volume of 1,500 mm 3 or the body weight lost >20% of original weight.
- Complexes as described herein may advantageously show a decreased tumor weight, indicative of efficacy, and retained body weight and indicative of a lack of toxicity, in contrast to e.g. DZ1-L-DOTA- 64 CU.
- Example 8 Image-guided therapy of prostate cancer
- mice of 4 - 6 weeks of age may be inoculated subcutaneously with human prostate cancer cells, e.g. C4-2B (also known as ATCC® CRL-3315TM and publicly available from American Type Culture Collection (ATCC), Manassas, Virginia) or ARCaP M , publicly available from NovicureTM, Birmingham, AL (ARCaPM cells, Catalog Number: 3422, are human prostate cancer cells established from a parental mixed ARCaP cell population with high propensity for bone metastasis in mice. Histopathology of the tumors in bone is mainly of osteoblastic lesions that recapitulate human prostate cancer bone metastasis.
- human prostate cancer cells e.g. C4-2B (also known as ATCC® CRL-3315TM and publicly available from American Type Culture Collection (ATCC), Manassas, Virginia) or ARCaP M , publicly available from NovicureTM, Birmingham, AL (ARCaPM cells, Catalog Number: 3422, are human prostate cancer cells established from a parental mixed ARC
- ARCaPM cells spindle-shape mesenchymal morphology
- ARCaPM are highly aggressive prostate cancer metastatic cells.
- ARCaPM cells can grow in culture using MCaP culture Medium available from NovicureTM. ARCaPM cells may be used to study prostate cancer bone metastasis and the role of EMT in cancer metastasis.
- MCaP -medium was prepared using Dulbeccos modified eagle and F12K medium and contains essential and non- essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors and trace minerals and supplemented with several factors that are critical for the optimal growth of ARCaP cells in vitro.
- the medium is serum-free and should be supplemented with 5% heat- inactivated Fetal Bovine Serum. It is bicarbonate buffered and has a pH of 7.4 when equilibrated in an incubator with an atmosphere of 5% C0 2 /95% air).
- mice may be kept for a suitably long duration, e.g. 2 weeks, for tumor formation to about 100 mm 3 in volume.
- the probe solution for injection will be prepared in sterile phosphate buffered saline (PBS) (radioactive doses of probe DZ-l-Lysine-CTC- 64 Cu complex).
- Mice may be administered intravenously (e.g. via tail vein) with the imaging probe in a suitable volume (e.g. a volume of about 100-150 pi), followed by procedures of blood collection, probe biodistribution, and fluorescence and PET imaging under inhalation anesthesia (e.g. 2% isoflurane in oxygen), as will be apparent to a person of ordinary skill.
- complexes as described herein may be administered e.g. as described herein to detect a primary tumor, and/or may be used to detect any residual metastases or secondary tumors thereof, e.g. after removal of a primary tumor, e.g. by surgery.
- Therapy and/or imaging may be performed in parallel or subsequently on a first and/or one or more secondary tumor, or metastases of a first or one or more secondary tumor using the complexes as described herein, optionally with parallel detection/imaging of residual metastases/tumors, and optionally followed by a first or further tumor therapy, or in case a first tumor therapy has been performed, a second or further tumor therapy and/or image-guided radiotherapy/detection of metastases/secondary tumors by imaging.
- Complexes as described herein may be particularly advantageous for imaging, therapy, and/or image-guided therapy of prostate cancer, including e.g. an improved serum stability, reduced toxicity, and significantly reduced metastatic bone tumor formation.
- Example 9 Image-guided therapy of brain tumors including glioblastoma
- experiments may be essentially performed as described herein-above under example 2.
- nude mice may be inoculated subcutaneously with human brain cancer cells (e.g.
- the therapeutic effects, efficacy and toxicity may be determined by inoculating nude mice intracranially with human brain cancer cells (e.g. neuroblastoma, astrocytoma, or glioblastoma cells publicly available from ATCC).
- human brain cancer cells e.g. neuroblastoma, astrocytoma, or glioblastoma cells publicly available from ATCC.
- n 5 mice per group.
- the probe solution for injection may be prepared in sterile PBS buffer.
- Mice may be administered intravenously (via tail vein) with imaging probes (PBS volume e.g. 100-150 pi) for blood collection, probe biodistribution, and fluorescence and PET imaging by intravenous injection e.g. via the mouse tail vein, e.g. using a syringe (e.g. 1/2 cc U-100 Insulin Syringe) under inhalation anesthesia (2% isoflurane in oxygen).
- Radioactive doses also known as probe, may be the DZ-1-(L)-CTC 64 Cu complex, formed as will be apparent to a person of ordinary skill and as generally described herein-above.
- One or more treatment administrations may be generally performed as described in example 5 herein above, with the following adjustments:
- the probe solution for injection may be prepared in sterile PBS buffer.
- Mice may be administered with imaging probes (PBS volume 100-150 m ⁇ ) for blood collection, probe biodistribution, and fluorescence and PET imaging e.g. by intravenous injection e.g. via mouse tail vein e.g. using a syringe (e.g. 1/2 cc U-100 Insulin Syringe) under anesthesia (2% isoflurane in oxygen).
- a brain tumor that is inoculated in the subcutaneous space may be surgically removed, optionally after detection using 64 Cu complexes as described herein.
- residual disease may be determined post-surgery and/or at intervals after surgery to detect resurgence using 64 Cu complexes as described herein.
- Treatment may be in parallel at the same dose, or altematively/additionally, upon detection of residual or resurgent metastases or tumors, treatment and prolonged and optionally higher dosed 64 Cu complexes may be initiated.
- the tumor in animals bearing an intracranial brain tumor, the tumor may be detected with 64 Cu complexes as described herein, and may be administered in a therapeutic dose to prevent or slow tumor growth, prevent or postpone animal death, and/or cause tumor shrinkage.
- Example 10 Stability and specificity of DZ-l-Lys-CB-TE2A with Copper-64
- Radiolabeling with 64 Cu may be performed as follows.
- the radiochemical purity (RCP) of 64Cu-DZ-l- Lys-CB-TE2A is measured by radio-HPLC (62% A to 20% in 15min, lmL/min; A: lOmM NH40Ac, B: acetonitrile; Atlantis T3 column, 4.6*150nm, 3 pm).
- the HPLC fractions from 10 - 12 min are collected and pooled (RCP > 95%) for the following biological evaluation experiments.
- Radio-HPLC analysis of 64Cu-DZ-l-Lys-CB-TE2A is shown in Fig. 1, with the top showing the UV channel at 780 nm, and the bottom showing the radio-channel.
- a serum stability assay may be performed as follows.
- Stability may be measured by radio-TLC in serum at 37°C. To 95 pL of serum 5 pL of 64Cu-DZ-l-Lys-CB-TE2A is added. The mixture was incubated at 37°C for 48 h. At time points of 2 h, 6 h, 24 h, and 48 h, the mixture was sampled for radio-TLC analysis, in which 400 pL of 50mM DTPA solution was used each time to assess the extent of 64Cu dissociation from 64Cu- DZ-l-Lys-CB-TE2A.
- Cancer cell lines in particular, human cancer cell lines, more specifically prostate cancer cell lines such as human DU145 prostate cancer cell lines, e.g. DU145vc (PTPN1 WT) and DU145sh (PTPN1 knockdown (KD)), may be obtained from the American Type Culture Collection (ATCC).
- DU145vc PTPN1 WT
- DU145sh PTPN1 knockdown
- ATCC American Type Culture Collection
- PTPN1 KD its expression is upregulated in androgen receptor (AR)-negative prostate cancer (e.g., castration-resistant prostate cancer) as compared to AR-positive prostate cancer.
- AR androgen receptor
- cancer cell lines may be used to establish cancer xenograft models in suitable mice, in particular in SCID mice.
- SCID mice prostate cancer xenograft models in SCID mice may be used.
- About ⁇ 1 x 10 6 cell suspensions of DU145vc and DU145sh may be injected subcutaneously, e.g. into the right and left shoulders of SCID mice, respectively. Post injection, mice are monitored for tumor growth in regular intervals.
- DU145vc and DU145sh tumors started growing three weeks post-injection. DU145vc tumors grew much quicker than DU145sh. When DU145sh became palpable, the size of DU145vc was already in the range of 500 - 1000 mm 3 .
- Small animal PET/CT Imaging may be performed as follows.
- the imaging study may start at tumor sizes of about 500 mm 3 or larger and may be performed on a suitable PET/CT imaging system, e.g. on a Siemens Inveon PET/CT Multimodality System (Knoxville, TN).
- DU145sh tumor size at the start was about 500 to about 1,000 mm 3
- DU145vc tumor size was between about 1,000 mm 3 to about 2,000 mm 3 .
- PET is followed by CT data acquisition, which may be conducted at 80 kV and 500 mA with a focal spot of 58 pm.
- Static scans may be performed at suitable intervals, e.g. at 4 h, 24, and 48 h post-injection of e.g.
- Fig. 4 A-C and Fig. 5 A-C for 64 Cu-DZ-l-Lys-CB-TE2A, substantial tumor uptake, good signal-to-noise ratio, high specificity and suitable clearance within 48 h to below 0.25 Standardized Uptake Value (SUV) is observed in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - Right shoulder) xenografts.
- SUV range from about 2.5 or more at 4h to between about 0.5 to about 2.5 at 24h, and about 0.125 at 48h, see in particular Fig. 3.
- Example 11 Comparative example with 64 Cu-DZ-l-NOTA shows its lack of specificity
- PC3 subcutaneous model small tumor volume ⁇ 100 mm3
- 64 Cu-DZ-l-NOTA -100 uCi/animal
- SCID mice were inoculated subcutaneously with lx lO 6 PC3 cells.
- PC3 or PC-3 is a cell line initiated from a bone metastasis of a grade IV prostatic adenocarcinoma that is publicly available from ATCC (CRL-1435TM). An IV injection is given and images are taken at various time points post-injection, as indicated (6, 24, 48h).
- a standardized uptake value is calculated based on isotope activity (from PET)/ volume of region of interest (from CT) /body weight and is shown for the tumor in Fig. 6 and Fig. 7A, Fig. 7B, and Fig. 7C.
- the SUV was about 0.3 at 6 hours p.i., increased to about 0.4 SUV at 24h p.i. and decreased to about 0.3 at 48h.
- a low target-to-background ratio is notable, see Fig. 7A, Fig. 7B, and Fig. 7C, and a low specificity of the 64 Cu-DZ-l-NOTA is observed .
- Complexes described herein may be particularly advantageous for imaging, therapy, and/or image-guided therapy of glioblastoma, including e.g. an improved serum stability, while retaining the ability to cross the blood-brain-barrier to improve animal survival.
- the complexes described herein may be used for cancer therapy as described herein-above.
- Many different options of administration and treatments are available and can be selected and applied depending on the individual subject and determined treatment protocol, as will be apparent to a person of ordinary skill.
- Features of one embodiment may be employed with other embodiments as the skilled artisan would recognize, even if not explicitly stated herein.
- Descriptions of well-known components and processing techniques may be omitted so as to not unnecessarily obscure the embodiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Optics & Photonics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Embodiments of the present invention relate to conjugates of the near infrared (NIR) heptamethine carbocyanine dye (HMCD) with chelator-radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, e.g. in internal radiotherapy and/or imaging of cancer. Provided are DZ-1-cross-bridged tetraamine cyclam (CTC) conjugates with optional linker L (DZ-1-(L)-CTC), wherein the CTC chelator is complexed with copper-64 (64Cu). The CTC may be a chelator selected from the group comprising CB-TE2A, DiAmSar, derivatives or combinations thereof. Copper complexes comprising DZ-1-(L)-CTC may provide improved serum stability compared to previously known copper complexes while retaining tumor targeting and providing good imaging quality. The present invention also relates to methods of forming the complexes, pharmaceutical compositions comprising the complexes, methods of using the complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, soft and solid tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like.
Description
HEPTAMETHINE CARBOCYANINE DYE-CROSS-BRIDGED TETRAAMINE CYCLAM (CTC) CHELATOR CONJUGATES, THEIR STABLE COMPLEXES WITH COPPER-64, AND USES THEREOF
FIELD OF THE INVENTION
[0001] Embodiments of the present invention generally relate to conjugates of the near infrared (NIR) heptamethine carbocyanine dye (HMCD) with chelator-radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, e.g. in internal radiotherapy and/or imaging of cancer. In particular, in embodiments, provided are DZ-1 -cross- bridged tetraamine cyclam (CTC) conjugates with optional linker L (DZ-l-(L)-CTC), wherein the CTC chelator is complexed with copper-64 (64Cu). More specifically the CTC may be a chelator selected from the group comprising CB-TE2A, DiAmSar, derivatives or combinations thereof. Copper complexes comprising DZ-1-(L)-CTC may provide improved serum stability compared to previously known copper complexes while retaining tumor targeting and providing good imaging quality. The present invention also relates to methods of forming the complexes, pharmaceutical compositions comprising the complexes, methods of using the complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, soft and solid tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like. Advantages of the embodiments may further include improved imaging and/or tumor detection, improved therapy of tumors, cancer, metastases, and pre-cancerous lesions, improved image guided therapy, and improved penetration of tumors, especially solid tumors. The complexes may allow to treat aggressive tumors that have few or no treatment options, particularly small round cell tumors, including tumors such as Ewing’s sarcoma (EWS), neuroblastoma, small cell lung cancer, Merkel cell tumors, and hormone-refractory prostate cancer (HRPC).
BACKGROUND
[0002] A limited number of diagnostic or therapeutic radiopharmaceuticals is available for imaging or treating cancer or tumors. Imaging takes advantage of the very low concentrations needed for detection, e.g. with Positron Emission Tomography (PET) detecting positron- emitters. Internal radiotherapy is a treatment in which a source of radiation is put inside the
subject’s body for cancer therapy. Internal radiation therapy may be systemic, i.e. the treatment travels in the blood to tissues throughout the body to kill cancer cells through the radiation that the cells in proximity to the radiometal are exposed to. Radiometals can be delivered by chelating or complexing them with a large variety of chelator compounds and conjugating them to a targeting ligand.
[0003] Radionuclide complexes currently used for such targeted radiotherapy are mostly diagnostic, with a limited number of therapeutic applications. The latter include various antibodies, proteins, and some smaller compounds, in particular peptides that are able to target certain types of cancer.
[0004] Examples of the use of radionuclides and radiometals for tumor imaging or adding imaging functionality to targeted cancer drugs include certain dye conjugates, namely near infrared (NIR) heptamethine carbocyanine dye (HMCD) conjugates. These were described for targeted cancer drug therapy and imaging, e.g. in WO 2016106324 and US 10,307,489 and include double-conjugated dye-drug-chelator conjugates wherein the dye is conjugated to a) anti cancer drug gemcitabine as well as b) an imaging moiety; one such imaging moiety is 64Cu- DOTA. The chelated/complexed radiometals are employed to provide imaging functionality to the cancer drug conjugates. A lysine-linked heptamethine carbocyanine dye conjugated with DOTA and complexed with Cu-64 (DZ-l-Lys-DOTA-Cu-64) was also described for imaging of cancer by Xiao et ah, Nuclear Medicine and Biology 40, p. 351-360 (2013) and e.g. in WO2016106324.
[0005] A problem with known radiometal complexes can be a lack of stability in the body, e.g. in blood and/or serum, which may result in insufficient performance, in particular in imaging performance and/or poor imaging quality (e.g. low signal strength, high noise, low signal/noise ratio, and/or resolution) when trying to detect small secondary tumors or metastases, as well as low efficacy and unnecessarily high radiation exposure with associated side effect and damage to non-cancerous tissues and organs.
[0006] Particular problems of copper radiometal chelates include poor bio-distribution and/or poor stability in vivo mediated by the chelator or radiometal or their combination, and which may
be caused by dissociation of copper from the chelator and/or binding of non-target tissues. Some chelates are subject to retention in non-target tissues such as the liver, kidney or other organs. Dissociation and binding of 64 Cu may prevent targeting to cancer cells or tumors as intended, and instead target, or rather, re-direct, 64Cu to other non-cancerous parts of the body and expose these parts to harmful radiation. Some radiometal chelates (or their dissociated products) show activity in other organs, e.g. liver, kidney, blood, bone, and/or bone marrow. For example, upon dissociation, 64Cu may bind to other proteins if the chelate-biomolecules were not sufficiently stable either kinetically and/or thermodynamically.
[0007] Still further problems with radiochemicals may include one or more of: lack of suitability for therapy for one or more cancer, insufficient sensitivity, insufficient selectivity for cancer cells, insufficient contrast between tumor and noncancerous tissues over time, insufficient biodistribution, insufficient tumor targeting, insufficient tissue and/or tumor penetration, insufficiently uniform distribution in tumor tissues, insufficient tumor accumulation ratios, insufficient retention in the tumor, slow clearance from the blood after administration, undesirably high radioactive exposure of tissues and organs, low clearance rate from important organs such as kidney, liver, heart etc., high radiation damage of non-targeted tissues or organs, in particular encapsulated tissues such as organs and dense tissues including tumor tissues, in particular calcified tumor tissues, slow establishment of steady state distribution in the body and organs including heart, liver, lungs and kidney, persistence of radioactivity in one or more organs including kidney and/or liver, no stable complex formation with one or more radiometal or difficulties to form stable complexes, low complex formation rates, low labelling efficiency with one or more radiometal, insufficient solubility in aqueous solutions, low stability in aqueous solutions, low stability at physiological pH, low stability in vivo , high rate of dissociation of the radiometal from the complex, in particular in vivo , slow tumor-specific targeting, high organ accumulation (e.g. kidney, spleen, liver, heart), slow clearance (e.g. from blood, liver, kidneys and other organs), and difficult or costly synthesis.
[0008] Various targeting ligand, chelator and radiometal combinations have been attempted for use in imaging, radiotherapy, or both, including matched pairs of the same targeting ligand for a theranostic approach. However, affinities of the targeting ligand for its receptor(s) have been
found to be strongly dependent both on the chelator and radiometal used, thus their efficacy often is unpredictable. Similar unpredictability applies to stability of the radiometal complexes, as retaining the radiometal may be influenced by the targeting ligand, chelator, or the combination thereof, and in turn their combination with a desired radiometal.
[0009] Radiotherapy tends to be even more challenging than mere imaging applications and options for treatment by radiotherapy are thus much more limited. Careful integration is needed for a suitable radionuclide in combination with a suitable chelator and a suitable targeting ligand to provide the desired characteristics including affinity, stability and pharmacokinetics. Particular radiometals may emit one or more type of particles or radiation at particular different percentages, and for suitable targeting careful coordination of carrier with a given radiometal is needed so that the complex is stable, sufficiently effective to destroy the target cancer but arrives at the location without causing collateral radiation damage to the not targeted rest of the body and its organs and tissues.
[0010] Some therapeutics can provide both therapy and diagnostic imaging to a degree, though for improved performance of each, theranostic pairs are often employed. A “true” theranostic pair would be an identical matched pair, i.e. have the same carrier for the therapeutic radiometal to destroy the tumor, and the imaging radiometal to allow to diagnostic and/or guided therapy. However, both chelator and radiometal affect important performance characteristics and pharmacokinetics, thus a given carrier may not be able to provide an identically matched pair with suitable characteristics, stability and efficacy for a desired radiometal combination. As an alternative, a non-identical matched pair may be used to adjust characteristics, provided that the binding affinities do not present clinically significant differences.
[0011] Agents or pairs of agents that can provide theranostic functionality thus often lack true theranostic functionality or other desirable characteristics, i.e. the ability to provide both sufficient therapeutic effect and sufficiently high imaging sensitivity at the same time and at similar pharmacokinetics, as well as favorable general pharmacokinetics, a high cytotoxicity for cancer cells but a low toxicity for non-cancerous cells.
[0012] A particular problem of radiochemicals is a high and persistent localization of the radioactivity being observed in certain organs, for example, without limitation, the kidneys, the liver, etc., which compromises tumor visualization in the region of the affected organ and limits therapeutic potential, e.g. for kidney or liver tumors and tumors localized in their area. Thus there is an interest in reducing organ radioactivity levels but not those in the target tissue(s). Radionuclide complexes also may encounter resorption by proximal tubules of the kidneys and/or adverse long residence times of radiometabolites in cells, particularly in renal cells, or cells of other organs, which may cause undesirably persistent radioactivity.
[0013] Therefore, there is a continued need in the art for radiopharmaceuticals that can provide improved radioimaging and/or improved radiotherapy, or both, and for radiopharmaceuticals with improved characteristics. In particular there is a need for radiopharmaceuticals with improved stability, in particular serum stability, reduced toxicity, increased effectiveness, and/or increased tumor penetration, favorable pharmacokinetics, among others. Further there is a need for theranostics that at allow both efficient therapy and imaging at the same time. Still further there is a need for therapeutics, imaging agents and theranostics that reduce or avoid damage to non-cancerous cells and tissues. These and other features and advantages of the present invention will be explained and will become apparent to one skilled in the art through the summary of the invention that follows.
SUMMARY OF THE INVENTION
[0014] In an embodiment, provided is a DZ-1-(L)-CTC conjugate, wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with an optional linker moiety L and a cross-bridged tetraamine cyclam (CTC) chelator residue R and as shown in FI below:
wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from the group consisting of CB- TE2A, DiAmSar, or a derivative thereof, wherein the optional linker L is a residue selected from the group comprising a Lysine residue, and wherein the chelator residue is complexed with 64Cu.
[0015] In an embodiment, provided is a complex wherein R is CB-TE2A, and wherein L is a lysine residue which links DZ-1 to the chelator as shown in FII below:
[0016] In an embodiment, provided is a complex wherein R is DiAmSar as shown in Fill below:
[0017] In an embodiment, provided is a complex provided with one or more pharmaceutically acceptable excipient to form a pharmaceutical formulation.
[0018] In an embodiment, provided is a complex provided as a kit with one or more reagents for reconstitution of the complex in an administrable form.
[0019] In an embodiment, provided is a kit provided with instructions for mixing and complexing the conjugate and 64Cu in suitable amounts, optionally with one or more reagent, buffer or excipient, and optionally treating the resulting solution containing the formed complex to provide it in an administrable form.
[0020] In an embodiment, provided is a method for imaging or treating cancer wherein a DZ-1- Lys-chelator conjugate complex of formula FI is administered to a subject suffering from cancer or from a risk to develop cancer in a sufficient amount and for sufficient duration to allow imaging or treatment; wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with a chelator residue R via a lysine linker and as shown in formula FI herein-above, wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from CB- TE2A, DiAmSar, or a derivative thereof, and wherein the chelator residue is complexed with 64Cu.
[0021] In an embodiment, provided is a method wherein R is CB-TE2A, and wherein L is a lysine residue which links DZ-1 to the chelator as shown in FII herein-above (DZl-Lys-CB- TE2A).
[0022] In an embodiment, provided is a method wherein R is DiAmSar as shown in Fill herein above (DZl-DiAmSar).
[0023] In an embodiment, provided is a method wherein imaging is performed by Positron Emission Tomography (PET) or Single-Photon Emission Computerized Tomography (SPECT) to detect 64Cu radiation, and optionally additionally by Computer Tomography (CT).
[0024] In an embodiment, provided is a method wherein imaging is performed before and/or during one or more therapy time intervals to provide an image-guided therapy.
[0025] In an embodiment, provided is a method wherein the risk to develop cancer is one or more genetic alteration associated with EWS, and the alterations include one or more alteration to a member of the ETS family of transcription factors.
[0026] In an embodiment, provided is a method wherein the cancer is selected from the group comprising: Ewing’s Sarcoma (EWS), a small cell round tumor, adult neuroblastoma, neuroblastoma in children, small cell lung cancer, Merkel cell tumors, Merkel cell tumors of the skin, prostate cancer, hormone-refractory prostate cancer (HRPC), neuroendocrine differentiated HRPC (NE-HRPC), pre-B-cell acute lymphoblastic leukemia, and a cancer which is associated with alterations in one or more member of the ETS family of transcription factors.
[0027] In an embodiment, provided is a method wherein the cancer is Ewing’s Sarcoma (EWS).
[0028] In an embodiment, provided is a method wherein R is CB-TE2A, or a derivative thereof.
[0029] In an embodiment, provided is a method wherein R is DiAmSar, or a derivative thereof.
DESCRIPTION OF THE DRAWINGS
[0030] Fig. 1 illustrates a radio-HPLC analysis of 64Cu-DZ-l-Lys-CB-TE2A. The top panel shows the UV channel at 780 nm, and the bottom panel shows the radio-channel. Fractions from 10 - 12 min contain the probe and were collected and pooled for use in Example 10.
[0031] Fig. 2 illustrates the high serum stability of 64Cu-DZ-l-Lys-CB-TE2A measured by radio- Thin Layer Chromatography (TLC) over time in hours in serum at 37°C (> 95%). The graph shows a high stability with no decline over the measured time period.
[0032] Fig. 3 illustrates the Standardized Uptake Value (SUV) observed in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts, ranging from about 2.5 or more at 4h to between about 0.5 to about 2.5 at 24h, and about 0.125 at 48h (i.e. substantially clearance from the body and its organs).
[0033] Fig. 4 A illustrates a substantial tumor uptake and retention, good signal-to-noise ratio and high specificity observed at 4 h in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts.
[0034] Fig. 4 B illustrates a substantial tumor uptake and retention, good signal-to-noise ratio and high specificity observed at 24 h in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - right shoulder) xenografts.
[0035] Fig. 4 C illustrates an efficient clearance profile including from the kidneys at 48 h (compare to 24 h in Fig. 4 B).
[0036] Fig. 5 A illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64Cu-DZ-l-CB-TE2A in tumors at 4 h.
[0037] Fig. 5 B illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64Cu-DZ-l-CB-TE2A in tumors at 24 h.
[0038] Fig. 5 C illustrates a maximum intensity projection (MIP) which demonstrates the uptake and retention of 64Cu-DZ-l-CB-TE2A in tumors at 48 h.
[0039] Fig. 6 illustrates low signal strength of Cu64-DZ-l-NOTA in a PC3 subcutaneous model.
[0040] Fig. 7 A illustrates low signal-to-noise ratio and low specificity of Cu64-DZ-l-NOTA in a PC3 subcutaneous mouse model at 4h.
[0041] Fig. 7 B illustrates low signal-to-noise ratio and low specificity of Cu64-DZ-l-NOTA in a PC3 subcutaneous mouse model at 24 h.
[0042] Fig. 7 C illustrates low signal-to-noise ratio and low specificity of Cu64-DZ-l-NOTA in a PC3 subcutaneous mouse model at 48 h.
DETAILED SPECIFICATION
[0043] Embodiments of the present invention generally relate to conjugates of the near infrared (NIR) heptamethine carbocyanine dye (HMCD) with chelator-radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, e.g. in internal radiotherapy and/or imaging of cancer. In particular, in embodiments, provided are DZ-1- cross- bridged tetraamine cyclam (CTC) conjugates with an optional linker L (DZ-l-(L)-CTC) wherein the CTC chelator is complexed with copper-64 (64Cu). More specifically the CTC may be a chelator selected from the group comprising CB-TE2A, DiAmSar, derivatives or combinations thereof. Copper complexes comprising DZ-1-(L)-CTC may provide improved serum stability compared to previously known copper complexes while retaining tumor targeting and providing good imaging quality. The present invention also relates to methods of forming the complexes, pharmaceutical compositions comprising the complexes, methods of using the complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, soft and solid tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like. Advantages of the embodiments may further include improved imaging and/or tumor detection, improved therapy of tumors, cancer, metastases, and pre-cancerous lesions, improved image guided therapy, and improved penetration of tumors, especially solid tumors. The complexes may allow to treat aggressive tumors that have few or no treatment options, particularly small round cell tumors, including tumors such as Ewing’s sarcoma (EWS), neuroblastoma, small cell lung cancer, Merkel cell tumors, and hormone-refractory prostate cancer (HRPC).
[0044] These DZ-l-(L)-CTC-64Cu complexes include DZ-l-CTC-64Cu and DZ-l-L-CTC-64Cu (with or without a linker), and may be referred to herein as “conjugate complexes”, “dye complexes”, “dye-chelator complexes”, “HMCD-chelator complexes”, “DZ-1 -chelator
complexes”, “radiometal complexes”, “64-Cu complexes”, “64Cu complexes” or simply “complexes”.
[0045] Unlike other DZ-l-chelator conjugates with 64Cu, the DZ-1 -cross-bridged tetraamine cyclam (CTC)-64Cu-complexes as described herein may have a higher stability in serum, e.g. as compared to a DZ1-DOTA-64CU complex (compare e.g. example 4).
[0046]Without wishing to be bound by theory, it is believed that the DZ1-CTC-64CU complexes may be suitable for treatment of various tumors including in particular various aggressive and difficult to treat tumors that currently lack adequate treatment options, such as Ewing’s Sarcoma (EWS) and other small cell round tumors.
[0047] Copper-64 (64Cu) is a positron emitter thus allowing use in PET imaging which can give real time images of physiological processes in the body in vivo thus allowing accurate monitoring, e.g. of drug distribution and biokinetics simultaneously.
[0048] Radiotherapy of cancer cells using 64Cu which is a beta emitter may have the advantage of providing a beneficial ratio of substantial damage to the target cells while not harming non target tissues, due to its limited range of radiation. This however requires highly stable complexes, which limit the cytotoxic effects of the radioactive 64Cu to its target. The stability of the 64Cu complexes may depend on the chelator it is complexed to, and in turn the delivery ligand that the chelator is bound to, the linker used, as well as the combination of these, their size, and the type and location of tumors.
[0049] In embodiments, provided are methods for image-guided radiotherapy wherein the complexes provide cancer radiotherapy, radioimaging of cancer, or both. At the same time, these complexes are believed to be sufficiently effective in tumor targeting, tumor shrinking and/or cancer cell killing, thus allowing a true theranostic approach with a single (rather than a pair) of therapeutics providing both diagnostic and therapy, which due to radioimaging such as PET has a high sensitivity. In addition, the dye’s fluorescence may be used for parallel fluorescent monitoring.
[0050] In embodiments, provided are radiometal complexes of a cross-bridged tetraamine cyclam (CTC) chelator selected from the group comprising CB-TE2A, DiAmSar, or derivatives thereof, conjugated, optionally via a linker such as a lysine linker (see formulae FI, FII and Fill shown herein below) to DZ-1, a heptamethine cyanine dye (HMCD), and compositions comprising these complexes, as well as compositions for making these complexes, e.g. in a test tube or kit, and the use of such compositions or complexes for the radiotherapy of cancer. The present invention also relates to methods of making the conjugates and complexes, pharmaceutical compositions including the complexes, methods of using the conjugates, complexes or pharmaceutical compositions, methods of imaging and/or radiotherapy of cancer cells, tissues, tumors, and/or their metastases, kits for imaging and/or radiotherapy, and the like. In addition, the present disclosure includes compositions used in and methods relating to non- invasive imaging, in particular PET or SPECT imaging, of the complexes in vivo. The complexes may be used for radio therapy of cancer cells and tissues, including of solid tumors. These compounds, including conjugates and resulting complexes, may have various advantages which may include an improved stability, reduced toxicity, and/or increased penetration of tumors.
[0051] In embodiments, the chelator conjugated to DZ-1 is a cross-bridged tetraamine cyclam (CTC), including CB-TE2A and DiAmSar, or derivatives thereof. Without wishing to be bound by theory, it is believed that cyclams, and in particular, cross-bridged cyclams, when in form of the conjugate, may contribute to the better stability of the resulting complexes with 64Cu. The improvement in stability e.g. in serum does not appear to be shared by conjugates to non-cross- bridged cyclen chelators such as e.g. DOTA.
[0052] CB-TE2A is a macrocyclic chelator also known as 1,4,8,11- Tetraazabicyclo[6.6.2]hexadecane-4,ll-diacetic acid and has the chemical formula C16H30N4O4 4HC1 (CAS #313229-90-2).
[0053] DiAmSar is a macrocyclic chelator also known as 1,8-Diamino-3,6,10,13,16,19- hexaazabicyclo[6,6,6]-eicosane and has the chemical formula CI4H34N8 5H20 (CAS # 91002- 72-1).
[0054] The chelator may be conjugated with DZ-1 directly via its terminal COOH residue, or via a suitable linker, for example a lysine residue. Alternatively, other suitable linkers may include alkyl linkers, e.g., without limitation, C2 to C15, e.g. C2, C3, C4, C5 or longer linkers, and polyethylene glycol linkers of varied chain length, e.g. (PEG)n with n=l-24, e.g. n=2-24. Other suitable linkers may include aminoacids or peptides, e.g. peptides of one or more aminoacids, e.g. up to 2, 3, 4, 5 or more amino acids linked together. Aminoacids used either as the linker or as one or more of its component in a peptide. Such amino acids may be selected from one or more of alanine (ala), arginine (arg), asparagine (asn), aspartic acid (asp), cysteine (cys), glutamine (gin), glutamic acid (glu), glycine (gly), histidine (his), isoleucine (ile), leucine (leu), lysine (lys), methionine (met), phenylalanine (phe), proline (pro), serine (ser), threonine (thr), tryptophan (trp), tyrosine (tyr), valine (val), or modifications or derivatives therof. Amino acids may be aliphatic (e.g. alanine, glycine, isoleucine, leucine, proline, valine), aromatic (phenylalanine, tryptophan, tyrosine), acidic (aspartic acid, glutamic acid), basic (arginine, histidine, lysine), or hydroxylic (serine, threonine), sulphur-containing (cysteine, methionine, or amidic (asparagine, glutamine). Preferred aminoacids may include lysine, glutamic acid, aspartic acid, cysteine, and preferred peptides may include peptides comprising one or more of lysine, glutamic acid, aspartic acid, cysteine.
[0055] Illustrative dye-linker-chelator compounds wherein R is a chelator as described herein and n is 1-20 (e.g. 1-10 or 1-5, e.g. 1, 2, 3, 4, or 5), are listed below:
[0056] In embodiments, provided is a DZ1-(L)-CTC radiometal complex which comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated, optionally via a linker as described herein, with a CTC chelator residue R, wherein R is selected from the group consisting of CB- TE2A, DiAmSar, or derivatives thereof, for radiolabelling with a 64Cu radiometal, and the resulting complex comprising 64Cu.
[0057] Illustrative DZ-1-(L)-CTC conjugates suitable to form such complexes are shown in formula FI below:
wherein L represents an optional linker comprising lysine, and R is selected from CB-TE2A and DiAmSar.
[0058] In embodiments, provided is a DZl-Lys-CB-TE2A radiometal complex for radiolabelling with 64Cu as shown below in formula FII:
[0059] In embodiments, provided is a DZl-Lys-DiAmSar conjugate for radiolabelling with 64Cu as shown below in formula Fill:
[0060] It is believed that the complexes described herein may provide one or more advantages including formation of radiometal complexes that have a higher stability, including in serum. Further the complexes may provide an effective cancer therapy with low toxicity and good tumor penetration even of solid tumors. In particular, the complexes are believed to provide true theranostic agents that may be able to provide both a highly effective radiotherapy while providing highly sensitive imaging, thus allowing an image-guided therapy without the necessity to administer a matched theranostic pair. The complexes may further provide one or more of the following advantages: a more accurate quantitative analysis via PET or SPECT probe and/or optionally near infrared fluorescence (NIRF), a higher contrast between tumor and noncancerous tissues, a higher sensitivity, a better selectivity for cancer cells, in particular in vivo , a rapid steady state distribution in the body and organs including heart, liver, lungs and kidney, rapid tumor targeting, a uniform distribution in tumor tissues, a lack of persistence of radioactivity in one or more organs including kidney and/or liver. Further, these complexes may advantageously be more easily formed and/or at lower cost, may be easily labelled with a radiometal, may form stable complexes with one or more radiometal, may have high complex formation rates, a high radiochemical yield, a good labelling efficiency with one or more radiometal, a good solubility in aqueous solutions, a high stability in aqueous solutions, a high stability at physiological pH of about 7.4 (e.g. 7.2-7.6), a high stability in vivo , a low rate of dissociation of the radiometal from the complex, in particular in vivo , a good biodistribution, sufficient targeting of the complex to cancer tissues, fast cancer-specific targeting, sufficient targeting for tumor and/or metastases, sufficient targeting for larger tumors, a low organ accumulation (e.g. kidney, spleen, liver, heart), no or reduced radioactive exposure of tissues and organs, a rapid clearance rate from important or sensitive organs (e.g. from blood, liver, kidneys and other organs) after administration, sufficient tissue and tumor penetration, sufficient penetration of encapsulated tissues such as organs including dense tissues including tumor tissues, in particular calcified tumor tissues, improved and/or longer retention in the tumor.
[0061] Radiochemical yield for the isotopes of a specified element is the yield of a radiochemical separation expressed as a fraction or percentage of the activity originally present. Also called the recovery. In radiation chemistry, the number of species transformed by radiation per eV of
absorbed energy: represented by the symbol G, the G-value. Radiochemical yield may be determined as will be apparent to a person of ordinary skill.
[0062] It is believed that the high stability of the complexes, including in serum, see examples herein-below, in addition to the combination with a CTC chelator and 64Cu, may contribute to one or more advantages as described herein.
[0063] Complexes as described herein may be able to penetrate more easily and more deeply into a tumor. These radiopharmaceuticals may thus be better suited for solid tumors, in particular denser and/or larger and/or partially calcified tumors.
[0064] Complexes as described herein may be able to provide blood-brain-barrier (BBB) penetration and thus may be used for treatment of brain tumors and brain metastases.
[0065] Complexes as described herein may be able to provide higher tumor accumulation ratios and/or a fast blood clearance. Distribution in animals may show a favorable time-dependent clearance in their organs concomitant with specific accumulation in tumors (e.g. xenograft tumors in mice, see e.g. example 6).
[0066] Complexes as described herein may be able to provide an improved percentage and/or speed of tumor uptake, e.g. as measured by % of injected dose (ID) of e.g. FI, FII or Fill (20 pg/kg) and the tumor-to-blood ratio at points in time (e.g. at 4, 8, 16 and/or 24 hours), as will be apparent to a person of ordinary skill.
[0067] Complexes as described herein may be able to provide increased dosing options and less accumulation and/or improved organ clearance from organs including one or more of kidneys, liver and heart. Organs such as the kidneys often are dose-limiting organs in radiotherapy. Absorbed doses may be measured as will be apparent to a person of ordinary skill, and may be e.g. about 15 Grays (Gy) or less, e.g. 10, 5, 2, 1 Gy or less.
[0068] Complexes as described herein may be able to provide a reduced absorbed dose to organs and/or soft tissues such as kidney, spleen, liver, and/or hematological toxicity (e.g. thrombocytopenia, neutropenia).
[0069] Complexes as described herein may be able to provide improved effectiveness against cancer at lower amounts of radioactivity. For example, less than 50 pCi, e.g. less than 20, 20, 5 or 2 pCi may be needed.
[0070] Complexes as described herein may be able to provide reduced toxicity at doses sufficient to treat cancer and/or significantly reduce tumor volume (e.g. by at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100%); thus a reduced LD50 and/or organ toxicity e.g. reduced kidney, spleen, liver, bone marrow, brain, heart or lung toxicity may be provided, and/or the complexes may allow to avoid or improve weight loss which often occurs during and after therapy.
[0071] Complexes as described herein may be able to provide reduced toxicity at doses sufficient to treat cancer and/or significantly reduce tumor volume while improving one or more of pain scores, bone pain scores, and median survival.
[0072] Complexes as described herein may be able to provide sufficient anti-cancer/anti-tumor effects at reduced total dose, for example less than 250 kBq/kg, e.g. less than 200, 150, 50, and 25 kBq/kg.
[0073] Complexes as described herein may be able to provide sufficient effectiveness to treat cancer and/or significantly reduce tumor volume while avoiding one or more side effects such as pain, dizziness, nausea, effects on the digestive tract, stomach pain, constipation, diarrhea, hair loss.
[0074] Complexes as described herein are believed to be particularly useful for Ewing’s sarcoma (EWS). EWS is an aggressive small round cell tumor of the bone and extra-osseous locations with metastases in lung, liver, brain. EWS is typically characterized by a signature chromosomal t(ll;22) translocation and EWS-FL1 fusion, typically affects young individuals (median age 15),
and generally responds to radiation and poly chemotherapy. However, when EWS is disseminated or recurrent, attempts of therapy are largely unsuccessful.
[0075] In embodiments, the complexes described herein may administered to a subject diagnosed with EWS and/or presenting with one or more genetic alteration associated with EWS, for imaging, therapy, or both, including image-guided therapy.
[0076] Without limitation, typical genetic alterations of EWS include one of several possible reciprocal chromosomal translocations that generate the fusion between the gene encoding Ewing’s sarcoma breakpoint region 1 (EWSR1) and a gene encoding a member of the E- twentysix (ETS) family of transcription factors, other genetic alterations exist, some of which are described for illustration herein-below. About 85 to 90% of cases may bear the chromosomal translocation t(l I;22)(q24;ql2), which can lead to the fusion of EWSR1 to the gene encoding Friend leukemia virus integration 1 (FLI1)2 (Fig. 2). In about roughly a quarter of the cases, the only detectable genetic event is the chromosomal translocation, with the resulting fusion protein likely responsible for transformation. Other mutations of other genes include, without limitation, STAG2 and TP53. While the vast majority of Ewing’s sarcomas harbor a fusion protein containing EWS, about 1% of the tumors bear chromosomal translocations that implicate FUS or TAF15 which like EWS are RNA-binding proteins that share a structure composed of an intrinsically disordered, low-complexity, prionlike SYGQ-rich N-terminal transactivation domain, followed by three arginine-and-glycine-rich (RGG) repeats of different lengths. RGG1 and RGG2 are separated by an RNA recognition motif consisting of 87 amino acids, and RGG2 and RGG3 by a zinc-finger domain. EWSR1 can partner not only with genes encoding ETS family members but also with a broad range of non-ETS genes to generate fusion proteins implicated in the pathogenesis of diverse soft-tissue tumors. These include, without limitation, EWSR1-NFATC2, EWSR1-POUF1, EWSR1-PATZ1, EWSRl-SMARCA, and EWSR1-SP3 which can give rise to rare, undifferentiated round-cell tumors either resembling Ewing’s sarcoma or considered to be Ewing’s sarcomas. Other EWSRl-non-ETS fusions give rise to well-defined entities, including, without limitation, DSRCT (EWSR1-WT1), myxoid liposarcoma (EWSR1-DDIT3), clear-cell sarcoma (EWSR1-ATF1), and extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3). Unrelated chromosomal translocations, which generate the
non-FET-non-ETS gene fusions BCOR-CCNB329 and CIC-DETX4,30 may give rise to tumors with morphologic features resembling those of Ewing’s sarcoma. These tumors were initially classified as Ewing’s sarcoma, but their pathogenesis and biologic properties are now believed to be clearly distinct from those of Ewing’s sarcoma. For example, at least 5 of the 27 members of the ETS family can fuse to EWS to generate Ewing’s sarcoma, these include, without limitation: FLIl, 2 ERG, 32 FEV,33 ETV1,34 and E1AF35; FLU may be found in 85 to 90% of cases. ETS factors may also be implicated in the development of diverse cancers, including pre-B-cell acute lymphoblastic leukemia and prostate cancer. All members of the family share a DNA-binding domain that recognizes the consensus core 5'-GGAA/T-3' DNA motif, often referred to as the ETS binding motif. FLIl has two ETS-binding domains separated by an FLIl-specific (FLS) sequence. The 5' ETS domain and the FLS sequence form the N-terminal transactivating domain, which is substantially less potent than the EWS N-terminal transactivating domain by which it is replaced in the fusion protein. For example, after chromosomal translocation, the portion of FLIl containing the 3' ETS-binding domain that becomes fused to EWS may undergo a conformational change, which may allow it to activate a broader repertoire of genes than wild- type FLI.
[0077] Typical genetic alterations of EWS include several possible reciprocal chromosomal translocations that generate the fusion between the gene encoding Ewing’s sarcoma breakpoint region 1 (EWSR1) and a gene encoding a member of the E-twentysix (ETS) family of transcription factors. About 85 to 90% of cases bear the chromosomal translocation t(ll;22)(q24;ql2), which leads to the fusion of EWSR1 to the gene encoding Friend leukemia virus integration 1 (FLI1)2 (Fig. 2). In roughly a quarter of the cases, the only detectable genetic event is the chromosomal translocation, with the resulting fusion protein likely responsible for transformation. Other mutations of other genes include, without limitation, STAG2 and TP53.
[0078] Other cancer types that the complexes as described herein may be used to successfully treat include other small cell round tumors, including, without limitation, neuroblastoma, in particular neuroblastoma in children, small cell lung cancer, Merkel cell tumors, in particular Merkel cell tumors of the skin, and euroendocrine differentiated HRPC (NE-HRPC).
[0079] Copper-64 (64Cu) may be technically produced by several different reactions as will be apparent to a person of ordinary skill, with the most common methods using either a reactor or an accelerator. Thermal neutrons can produce 64Cu in low specific activity (the number of decays per second per amount of substance) and low yield through the 63Cu(n,y)64Cu reaction. Alternatively, 64Cu may be produced using high-energy neutrons via the 64Zn(n,p)64Cu reaction in high specific activity but low yield. Using a biomedical cyclotron the 64Ni(p,n)64Cu nuclear reaction may produce large quantities of the nuclide with high specific activity.
[0080] In embodiments, radiotherapy as described herein may be improved by pairing such therapy with Positron Emission Tomography (PET) or SPECT and/or to provide image-guided therapy. Alternatively, the complexes as described herein may be used for imaging only, or therapy only. PET detects positron-emitters such as 64Cu, and may optionally be combined with Computerized Tomography (CT) imaging, i.e. PET/CT. In CT, x-ray scans are taken from different angles with the various slices arranged in 3D by a computer which may be used as a map to overlay with signals detected by PET.
[0081] In embodiments, radiotherapy may be performed internally, i.e. a source of radiation may be provided inside the subject’s body for cancer therapy. Internal radiation therapy may be performed systemically, thus the treatment travels in the blood to tissues throughout the body to kill cancer cells in a targeted fashion trough the radiation the cells in proximity to the radiometal are exposed to. In embodiments, treatment may be through systemic or localized/site-specific administration, such as oral or intravenous injection for systemic administration, or localized injection or deposits, e.g. through use of seeds in brachytherapy of accessible tumors, as will be apparent to a person of ordinary skill. Using the stable complexes provided, the radiometals can be delivered to tumors and metastases in a targeted fashion.
[0082] In embodiments, one or more radiometal complex may be administered in a coordinated administration protocol.
[0083] In embodiments, imaging may be performed before and/or during one or more therapy time intervals to provide an image-guided therapy. The amount, concentration, duration and form of administration will be adjusted accordingly, as will be apparent to a person of ordinary skill.
For example, imaging may allow to locate a suspected tumor, e.g. after genetic testing revealed a genetic alteration and pre-disposition, e.g. for a particular type of cancer, tumor or group of tumors, such as, without limitation, EWS. After location of the tumor or cancer, therapy may be performed, either systemically (e.g. systemic administration such as by IV or orally), or localized administration restricted to the tumor site and its surroundings (e.g. by localized injection). Alternatively, imaging and therapy may be performed in the same step. Still alternatively, imaging may be performed one or more times before and over the course of therapy to monitor tumor development and, upon therapy, shrinkage.
[0084] Without wishing to be bound by theory, it is believed that the DZ-1-(L)-CTC conjugates form complexes of high thermodynamic stability and kinetic inertness with 64Cu, and will rapidly, quantitatively and stably coordinate with the radiometal at room temperature (at about 20 DEG C, or e.g. at less than 25, 30, 35, 40, 45, 50, 55, 60, 65, 70 or 75 DEG C), near neutral pH (at about 7, e.g. about 5 or more, about 6 or more, about 8 or less, about 7.5 or less), and at a low DZ-l-Lys-DOTA concentration, e.g. 0.1-100 micromolar or nanomolar, e.g. about 1 to about 20 micromolar, e.g. about 1 to about 10 micromolar, e.g. about 5-8 micromolar, allowing to easily provide radiopharmaceutical formulations.
[0085] Complexes as described herein may provide superior imaging during detection including e.g. PET, in particular one or more of better signal-noise ratio, stronger signal, and better resolution.
[0086] Complexes as described herein, may be suitable for tumors of all sizes with effects including tumor shrinkage, and, due to increased stability, in vivo distribution and/or imaging sensitivity, may be particularly effective to detect and destroy small tumors or metastases of a volume of less than e.g. about 5 to about 0.1 cm3 or less, e.g. about 5 cm3 or less, about 4 cm3 or less, about 3 cm3 or less, about 2 cm3 or less, about 1 cm3 or less, about 0.5 cm3 or less, about 0.1 cm3 or less. Where not otherwise indicated, tumor volumes apply to human patients typically having a weight of about 140 to 200 lb, e.g. about 170 lb. In non-human subjects tumor volumes will be less or more depending on body weight. Advantages may include a significant reduction or removal of metastases, higher absorbed doses, and/or a lower tissue penetration range.
[0087] Complexes as described herein, due to increased stability and/or improved tumor penetration, may be particularly effective to also destroy larger tumors, in particular solid tumors, of a volume of more than e.g. about 5 cm3, e.g. about 5 cm3 to about 2000 cm3 or more, e.g. about 50, 100, 200, 500 or 1000 cm3 or more.
[0088] Complexes as described herein may be suitable for tumors of all sizes with effects including tumor shrinkage. Advantages may include a significant reduction or removal of metastases, higher absorbed doses, and/or a lower tissue penetration range.
[0089] In embodiments, Positron Emission Tomography (PET) may be used to provide data on radiometal distribution within target tissues by detection of gamma photons resulting from the decay of the radiometals. High spatial resolution of commonly available PET scanners allows to visually map radiometal decay events and thus provide an image which reflects the distribution of a radiometal in the body after administration of a radiometal complex. Such images provide anatomic and functional information to aid medical diagnosis and assist to track progress and allow adjustment of radiotherapy.
[0090] In embodiments, cancer as referred to herein includes precancerous and cancerous cells or tissues, tumors and their metastases, primary and secondary tumors. The conjugates and methods described herein may be particularly advantageous for use in brain cancers, brain tumors and their metastases. Without wishing to be bound by theory it is believed that CB-TE2A, DiAmSar, or derivatives thereof, in combination with DZ1 and 64 Cu as described, and in particular when conjugated via a lysine linker, allows the radioactive conjugates to pass across the blood-brain barrier and allow imaging and therapy throughout the brain, including tumors located deep within the brain structure that often are not or not efficiently accessible by other methods and may be inoperable.
[0091] In embodiments, the cancer treated by the complexes may be selected from the group comprising: brain cancer, prostate cancer, lung cancer, Non-small-cell lung carcinoma (NSCLC), small-cell lung carcinoma (SCLC), pancreatic cancer, kidney cancer, lymphoma, colorectal cancer, skin cancer, HCC cancer, and breast cancer, squamous-cell carcinoma of the lung, anal cancers, epithelial tumors of the head and neck, bone cancer, carcinoma of the cervix, skin
cancer, melanoma, hematopoietic cancers, lymphoma, and myeloma, or metastases of any thereof, including e.g., without limitation, metastases occurring in the brain, the bone, or other organs, brain tumors or their metastases, brain tumors and their brain, bone, lung or other organ metastases, bone tumors or their brain, bone, lung or other metastases, prostate tumors or their brain, bone, lung or other metastases, prostate tumors and their brain, bone, lung or other metastases, lung tumors and their brain, bone, lung or other metastases, and others.
[0092] In embodiments, the cancer may be a central nervous system (CNS) or brain tumor, or metastasis thereof, selected from the group comprising: acoustic neuroma, astrocytoma, chordoma, CNS lymphoma, craniopharyngioma, glioma, glioblastoma, medulloblastoma, meningioma, oligodendroglioma, pituitary tumors, primitive neuroectodermal tumor, Schwannoma, brain stem glioma, ependymoma, juvenile pilocytic astrocytoma, optic nerve glioma, pineal tumor, rhabdoid tumor, adult Low-Grade (WHO Grade I or II) Glioma/Pilocytic, Infiltrative Supratentorial Oligodendroglioma, Anaplastic Gliomas/Glioblastoma, Adult Intracranial Ependymoma, Adult Medulloblastoma, Primary CNS Lymphoma, Primary Spinal Cord Tumors, Limited Brain Metastases, Extensive Brain Metastases, Leptomeningeal Metastases, and Metastatic Spine Tumors.
[0093] In embodiments, the cancer may be a Non-small-cell lung carcinoma selected from a Squamous-cell carcinoma, Adenocarcinoma (Mucinous cystadenocarcinoma), Large-cell lung carcinoma, Rhabdoid carcinoma, Sarcomatoid carcinoma, Carcinoid, Salivary gland-like carcinoma, Adenosquamous carcinoma, Papillary adenocarcinoma, and Giant-cell carcinoma. Alternatively, the cancer may be a small-cell lung carcinoma, including a Combined small-cell carcinoma. Alternatively, the cancer may be a non-carcinoma of the lung, including a Sarcoma, Lymphoma, Immature teratoma, and Melanoma.
[0094] In embodiments, a pharmaceutical composition comprising a radiometal complex, or for forming such complexes, is provided. The pharmaceutical composition may be for human or for veterinary use, and comprise one or more conjugate or complex of the invention (or a salt, solvate, metabolite, or derivative thereof) with one or more pharmaceutically acceptable carrier and/or one or more excipient and/or one or more active. The one or more carrier, excipient
and/or active may be selected for compatibility with the other ingredients of the formulation and not unduly deleterious to the recipient thereof. Such carriers are known in the art and may be selected as will be apparent to a person of ordinary skill in the art.
[0095] In embodiments, routes of administration for the compounds and pharmaceutical compositions include, but are not limited to: oral (e.g. in pill form), intravenous (i.e. injected into a subject’s vein), interstitially (i.e. inserted into a space in the body), intraperitoneal, subcutaneous, or intramuscular, and/or by brachytherapy (insertion of radioactive implants or seeds directly into the affected tissue, e.g. into or near a tumor location). Administration may be systemic (e.g. via blood circulation) or regional (e.g. localized to a particular organ of the body or part thereof). In some embodiments, the pharmaceutical compositions of the invention contain a pharmaceutically acceptable excipient suitable for rendering the compound or mixture administrable via the above routes of administration.
[0096] In embodiments, the active ingredients can be admixed or compounded with a conventional, pharmaceutically acceptable excipient or carrier. A mode of administration, vehicle, excipient or carrier should generally be substantially inert with respect to the active agent, as will be understood by those of ordinary skill in the art. Illustrative of such methods, vehicles, excipients, and carriers are those described, for example, in Remington: The Science and Practice of Pharmacy (2020), ISBN-10: 0128200073, or in Handbook of Pharmaceutical Excipients, Ninth edition (2020), ISBN-10: 0857113755, the disclosures of which is incorporated herein by reference. The excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
[0097] In embodiments, the pharmaceutical formulations may be conveniently made available in a unit dosage form by any of the methods generally known in the pharmaceutical arts. Generally speaking, such methods of preparation comprise presenting the formulation in a suitable form for delivery, e.g., forming an aqueous suspension. The dosage form may optionally comprise one or more adjuvant or accessory pharmaceutical ingredient for use in the formulation, such as mixtures, buffers, and solubility enhancers.
[0098] According to an embodiment of the present invention, parenteral dosage forms (i.e. that bypass the GI tract) of the pharmaceutical formulations include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. In addition, controlled-release parenteral dosage forms can be prepared for administration of a patient, including, but not limited to, administration DUROS®-type dosage forms, and dose-dumping.
[0099] In embodiments, suitable vehicles that can be used to provide parenteral dosage forms of the compounds of the invention include, without limitation: sterile water; water for injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to, sodium chloride injection, Ringer's injection, dextrose Injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol, polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate. Compounds that alter or modify the solubility of a pharmaceutically acceptable salt of a compound of the invention as disclosed herein can also be incorporated into the parenteral dosage forms of the disclosure, including conventional and controlled-release parenteral dosage forms.
[0100] In embodiments, formulations for parenteral administration include aqueous and non- aqueous sterile injection solutions, which may further contain additional agents, such as anti oxidants, buffers, bacteriostats, and solutes, which render the formulations isotonic with the blood of the intended recipient. The formulations may include aqueous and non-aqueous sterile suspensions, which contain suspending agents and thickening agents.
[0101] In embodiments, injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be employed are water, Ringer’s solution, U.S.P. and isotonic sodium chloride solution.
In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0102] In embodiments, forms suitable for oral administration include tablets, troches, capsules, elixirs, suspensions, syrups, wafers, or the like prepared by art recognized procedures. The amount of active compound in such therapeutically useful compositions or preparations is such that a suitable dosage will be obtained. A syrup formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier, for example, ethanol, glycerine or water, with a flavoring or coloring agent.
[0103] In embodiments, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcelhdose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form can also comprise buffering agents.
[0104] In embodiments, solid compositions of a similar type can be employed as fillers in soft and hardfilled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a
delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type can also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, and the like.
[0105] In embodiments, the active compounds conjugates or complexes can be in micro- encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art. In such solid dosage forms the active compound can be admixed with at least one inert diluent such as sucrose, lactose and starch. Such dosage forms can also comprise, as in normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such as magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms can also comprise buffering agents. They can optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.
[0106] In embodiments, the active compounds, conjugates or complexes can be present in form of salts, which may be particularly suitable for use in the treatment of cancer. The salts of the present invention may be administered to the patient in a variety of forms, depending on the route of administration, the salt involved, and the cancer being treated. For example, an aqueous composition or suspension of the salts may be administered by injection, or in the form of a pharmaceutical matrix by injection or surgical implantation, at a desired site. The particular technique employed for administering the matrix may depend, for example, on the shape and dimensions of the involved matrix. In some embodiments, the salt is introduced substantially homogeneously in a tumor to minimize the occurrence in the tumor of cold (untreated) areas. In certain embodiments, the salt is administered in combination with a pharmaceutically acceptable carrier. "Pharmaceutically acceptable carrier" refers to an excipient that can be included in the compositions of the invention and that causes no significant adverse toxicological effects to the
patient. A wide variety of pharmaceutically acceptable carriers or excipients are available and can be combined with the present salts, as will be apparent to one of ordinary skill in the art.
[0107] According to an embodiment of the present invention, effective amounts, toxicity, and therapeutic efficacy of the active compounds conjugates or complexes can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dosage can vary depending upon the dosage form employed and the route of administration utilized. The dose ratio between toxic and therapeutic effects is the therapeutic index and can be expressed as the ratio LD50/ED50. In some embodiments, compositions and methods exhibit large therapeutic indices. A therapeutically effective dose can be estimated initially from cell culture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the compound of the invention, which achieves a half- maximal inhibition of symptoms) as determined in cell culture, or in an appropriate animal model. Levels in plasma can be measured, for example, by high performance liquid chromatography. The effects of any particular dosage can be monitored by a suitable bioassay. The dosage can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment.
[0108] In embodiments, the dosage of a pharmaceutical formulation as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen. The dosing schedule/regimen can vary, e.g. once a week, daily, or in particular predetermined intervals, depending on a number of clinical factors, such as the subject's sensitivity to each of the active compounds.
[0109] In embodiments, an effective dose of a composition comprising radiometal complex can be administered to a patient once. Alternatively, an effective dose of a composition comprising a radiometal complex can be administered to a patient repeatedly. The radiometal complex can be administered over a period of time, such as over a 5 to 60 minute period, e.g. about 30 minutes. If warranted, the administration can be repeated, for example, on a regular basis, such as hourly, daily, bi-weekly or weekly, e.g. in a suitable time interval of e.g. about 6, 12, 24, 48 or 72 hours. In some instances, after an initial treatment regimen, the treatments can be administered on a less frequent basis. For example, after an initial administration, administration can be repeated once per week, month, six months or a year or longer.
[0110] In embodiments, the amount of the active compound, conjugate or complex in the pharmaceutical composition can be based on weight, moles, or volume. In some embodiments, the pharmaceutical composition comprises at least 0.0001%, 0.1%, 0.5% 1%, 2%, 3%, 4%, 5% or 10% of the active. In some embodiments, the pharmaceutical composition comprises 0.01%- 99% of the active, e.g. 0.05%-90%, 0.1%-85%, 0.5%-80%, l%-75%, 2%-70%, 3%-65%, 4%- 60% or 5%-50% of the active.
[0111] The dosage of a composition as described herein can be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. With respect to duration and frequency of treatment, it is typical for skilled clinicians to monitor subjects in order to determine when the treatment is providing therapeutic benefit, and to determine whether to increase or decrease dosage, increase or decrease administration frequency, discontinue treatment, resume treatment, or make other alterations to the treatment regimen. The dosing schedule can vary from once a week to daily depending on a number of clinical factors, such as the subject's sensitivity to the compound of the invention.
[0112] In embodiments, in addition to treating cancer (pre-cancerous or cancerous cells and tumors) in a subject in need thereof, such cancer is identified, imaged and/or localized. The method may comprise providing a radiometal complex; administering the complex to a subject; and optionally performing imaging, e.g. PET imaging, to detect the emitter released. This allows to visually follow tumor growth and/or shrinkage, e.g. to confirm or personalize an optimized
dosage, and/or determine the location of tumor(s) and/or metastases. In various embodiments, imaging may be performed, for example, about 6 to 48 hours post administration. Imaging may be performed in comparison to normal tissue/cells to determine uptake rates differing in cancer/tumor tissues versus normal tissues.
[0113] In embodiments, in situ pharmacokinetic and pharmacodynamic analyses in a tumor or normal cell or tissue may be performed. The method can comprise providing the complex; contacting it with the cancer cells, tumor, or normal cell or tissue; and imaging the cancer cells, tumor, or normal cell or tissue, followed by pharmacokinetic and/or pharmacodynamics analyses, e.g. determining the signal (including radioactivity and/or NIR fluorescence, and changes thereof, at one or more point of time over time, e.g. before and after administration, and one or more times after administration.
[0114] In embodiments, a kit for providing or making a radiopharmaceutical preparation comprising a radiometal complex is provided. In general a vial containing the nonradiometal components of a radiopharmaceutical preparation, usually in the form of a sterilized, validated product to which the appropriate radiometal is added or in which the appropriate radiometal is diluted before use. One or more kit component may be provided in form of an optionally buffered solution, or may be provided for dissolution in an optionally buffered solution. For example, the kit may be a single or multidose vial, and the radiopharmaceutical preparation may require additional steps, e.g., without limitation, boiling, heating, filtration and/or buffering. Radiopharmaceutical preparations derived from kits generally are intended for immediate use after preparation, e.g. within 6-24 hours, e.g. within about 12 hours of preparation.
[0115] The kit can also further comprise conventional kit components, such as needles for use in injecting the compositions, one or more vials for mixing the composition components, and the like, as are apparent to those of ordinary skill. In addition, instructions, either as inserts or as labels, indicating quantities of the components, guidelines for mixing the components, and protocols for administration, can be included in the kits.
[0116] The concentration of the complexes employed in the pharmaceutical compositions and/or the amount administered to a patient or subject may vary and depends upon a variety of factors
including, for example, the particular complex and/or pharmaceutically acceptable carrier employed, the particular disease being treated, the extent of the disease, the size and weight of the patient, and the like. Typically, the complex may be employed in the pharmaceutical compositions, and the compositions may be administered to a patient to provide initially lower levels of radiation dosages which may be increased until the desired therapeutic effect is achieved. Generally speaking, the complexes may be employed in pharmaceutical compositions which comprise an aqueous carrier to provide a concentration of absolute radioactivity which may range from about 4 MBq per milliliter (ml) (about 0.1 mCi/ml) or less to about 370 MBq/ml (about 10 mCi/ml), and all combinations and subcombinations of ranges therein. In embodiments, the concentration of the complex in the pharmaceutical compositions may be from about 37 MBq/ml (about 1 mCi/ml) to about 370 MBq/ml (about 10 mCi/ml). In addition, the compositions may be administered to a patient to provide a radiation dose which may range from about 1 KSv (about 1x105 Rem) to about 74 KSv (about 7.4 MRem), and all combinations and subcombinations of ranges therein. In embodiments, the compositions may be administered to a patient to provide a radiation dose of from about 7.4 KSv (about 7.4x105 Rem) to about 74 KSv (about 7.4 MRem). Such amounts are referred to herein as effective amounts or therapeutically effective amounts. In embodiments, the pharmaceutically acceptable carrier may further comprise a thickening agent.
[0117] Thickening agent refers to any of a variety of generally hydrophilic materials which, when incorporated in the present compositions, may act as viscosity modifying agents, emulsifying and/or solubilizing agents, suspending agents, and/or tonicity raising agents. Thickening agents which may be suitable for use in the present radiopharmaceutical compositions include, for example, gelatins, starches, gums, pectin, casein and phycocolloids, including carrageenan, algin and agar, semi -synthetic cellulose derivatives, polyvinyl alcohol and carboxyvinylates, and bentonite, silicates and colloidal silica. Other thickening agents would be apparent to one of ordinary skill.
[0118] The concentration of thickening agent may range from about 0.1 to about 500 milligrams (mg) per ml of pharmaceutical composition. In certain embodiments, the concentration of thickening agent may be from about 1 to about 400 mg/ml, e.g. from about 5 to about 300
mg/ml, e.g. from about 10 to about 200 mg/ml, e.g. from about 20 to about 100 mg/ml, or e.g. from about 25 to about 50 mg/ml. Compositions which may be prepared from the complexes, pharmaceutically acceptable carriers and optional thickening agents include, for example, suspensions, emulsions, and dispersions. In some embodiments, the complexes can be formulated and administered to a patient as a suspension.
[0119] Suspension may refer to a mixture, dispersion or emulsion of finely divided colloidal particles in a liquid. Suspensions may be obtained, for example, by combining the complexes with an inert solid support material. Particulate support materials which may be suitable for use as an inert solid support in the compositions of the present invention include, for example, materials derived from carbon, including those forms of carbon typically referred to as carbon black (lampblack) and/or activated carbon, as well as finely powdered oxides, Kieselguhr, and diatomaceous earth. In some embodiments, the support material comprises carbon black or activated carbon. The size of the particles of the particulate support material may vary and depends, for example, on the particular support material, complex, thickening agent, and the like, employed and may comprise particles ranging in size, for example, from about 0.1 micrometer (mm) to about 50 mm, e.g. the particle size may be from about 0.5 to about 25 mm, e.g. from about 1 to about 10 mm, e.g. from about 2 to about 5 mm.
[0120] Delivery of a therapeutically effective activity of a complex can be obtained via administration of a pharmaceutical composition comprising a therapeutically effective activity or dose of the complex, i.e. in a concentration that is sufficient to elicit the desired therapeutic or imaging effect according to the methods described herein. A therapeutically effective activity may be an activity effective to treat cancer, such as inhibiting or slowing growth of cancerous or precancerous tissue, or lowering the survival rate of cancer or pre-cancerous cells. The therapeutically effective dosage will vary somewhat patient to patient, and will depend upon the condition of the patient and the route of delivery. The effective activity of any particular compound would be expected to vary according to the weight, sex, age, and medical history of the subject. Other factors which influence the effective dose can include, but are not limited to, the severity of the patient's condition, the disease or disorder being treated, the stability of the complex, and, if appropriate, any additional antineoplastic therapeutic agent being administered
with the complex. Methods to determine efficacy and dosage are known to those of ordinary skill.
[0121] Exemplary illustrative embodiments
[0122] Example 1 - Synthesis of DZ-1-(L)-CTC chelator conjugate radiometal complexes
[0123] The synthesis of the DZ-1 dye and its derivatives has been previously described, e.g. in US 10,307,489, which is hereby incorporated herein in its entirety, and may be performed, for example, as described in detail in example la below. The conjugate may then be complexed with radiometals as described in example lb. The following chemicals and reagents may be used. [0124] The CTC chelators CB-TE2A and DiAmSar can be purchased from Macrocyclics (Plano, TX). All other chemicals mentioned herein, e.g. in the reaction schemes as shown, may also be purchased from various standard sources, for example VWR International (Radnor, PA) or Thermo Fisher Scientific (Waltham, MA), as will be apparent to a person of ordinary skill. Deionized ultrapure water (18.2 MW) may be used for making solutions which may be obtained from Milli-Q Direct Ultrapure Water System from Millipore (Billerica, MA, USA). Analytical reversed-phase (RP) high-performance liquid chromatography (HPLC) may be performed e.g. on an Agilent system, e.g. with a 1260 Infinity Diode-Array Detector, e.g. with an Apollo C18 RP column (5 pm, 150 x4.6 mm). For example, the mobile phase may change from 60% solvent A (e.g. 0.1% trifluoroacetic acid in 80% water) and 40% solvent B (e.g. 0.1% trifluoroacetic acid in 80% aqueous acetonitrile) to 100% solvent B over a period of e.g. about 30 min at a flow rate of about 1 ml/min monitoring at e.g. about 254 and/or about 780 nm). Electrospray Ionization Mass Spectrometry (ESI-MS) analysis may be performed on the synthesized compounds, e.g. on a Thermo TSQ Fortis Triple Quadrupole mass spectrometer system.
[0125] DZ-1 may be synthesized e.g. as described below, then it may be conjugated directly to a CTC, or alternatively, a linker may be used to link DZ-1 with a CTC, e.g. a lysine linker, e.g. as shown in scheme 2 herein-below, e.g. to form DZ-l-Lys-CB-TE2A, as shown e.g. in scheme 3 herein-below, or DZl-Lys may be linked to another CTC, e.g. without limitation, DZ-l-Lys- DiAmSar (not shown). Alternatively, as illustrated herein-below in scheme 5 for DiAmSar, DZ-1 may be directly linked to a CTC. The resulting DZ-1-(L)-CTC conjugate, with or without linker
L, may then be subjected to 64Cu radiolabeling (shown herein-below in schemes 4 and 6, respectively).
[0126] Example 1 - Synthesis of DZ-1-(L)-CTC conjugates
[0127] Scheme 1 shown below illustrates the first steps of conjugate synthesis forming a DZ-1- (L)-CTC conjugate, showing synthesis of dye compound 4, also referred to herein as “DZ-1”; alternative routes of synthesis will be apparent to a person of ordinary skill.
[0129] Synthesis of compound la (compare scheme 1 above): The mixture 2, 3, 3- trimethylindolenine (5 g, 31.4 mmol) and 1,4-butane sultone (5.1 g, 37.7 mmol) may be heated with stirring at 120°C under argon for 5 h. The resulted reaction mixture may be cooled to RT (e.g. about 20°C) and the solid may be dissolved in a sufficient volume of solvent, e.g. and organic solvent, e.g. about 50 ml of methanol. Ethyl ether, e.g. about 200 ml, may be added to the methanol solution for precipitation, and the precipitate may be collected and washed with a sufficient volume a sufficient number of times of ethyl acetate (e.g. 15 ml, three times) and dried, e.g. under vacuum, to afford desired product 6.8 g (yield 73%) as a white solid.
[0130] Synthesis of compound lb (compare scheme 1 above): To 6-Bromohexanoic acid (2.5 g, 13.0 mmol) may be added 2, 3, 3-trimethylindolenine (2.5 g, 15.7 mmol). The reaction mixture may be heated with stirring at a sufficiently elevated temperature, e.g. at about 110°C under a protective gas such as argon for 8 h. The resulting dark red solid may be dissolved in 50 ml of methanol. Ethyl ether 150 ml may be added. The precipitate may be filtered and washed a sufficient number of times and volume e.g. with ether (e.g. 15 ml, three times) followed by a sufficient number of volume and times washing with acetone (e.g. 15 ml, three times). The product obtained is a white solid (2.7 g, 58%).
[0131] Synthesis of compound 3 (compare scheme 1 above): To the mixture of la (2 g, 6.78 mmol) and compound 2 (3 g, 8.36 mmol) in EtOH (100ml) may be added CH3COONa (0.28 g, 3.39 mmol), the resulted mixture may be heated at a sufficient temperature and duration, e.g. about 60 °C for about 18 hours. The precipitate may be filtered and sufficiently washed with cold ethanol (e.g. 20 ml, three times). The product may be dried under vacuum to afford desired product 3 as a dark blue solid (2.1 g, yield 58%). Mass spectrum (ESI) 525.19 [M+H]+.
[0132] Synthesis of compound 4, a heptamethine cyanine dye, also referred to herein as DZ- 1 (compare scheme 1 above): To the mixture of lb (0.67 g, 1.9 mmol) and compound 3 (1.0 g, 1.9 mmol) in EtOH (20 ml) may be added CH3COONa (156 mg, 1.9 mmol), the resulting solution may be heated to reflux for a sufficient time, e.g. 3 h. The mixture may then be subjected to precipitation, e.g. kit may be poured into 100 ml of ice water. The solid may be filtered and crystallized from methanol-water to afford desired product 4 as a dark green solid (0.99 g, yield 74%). Mass spectrum (ESI) 705.31 [M+H]+.
[0133] Scheme 2 below shows a synthesis of a dye conjugated to a suitable linker moiety DZ-l-L, here of DZ-l-Lysine:
[0134] Synthesis of DZ-l-Lysine (compare scheme 2 above): DZ-1 4 (200 mg, 0.28 mmol) may be dissolved in 5 ml anhydrous CH2CI2. Ethyl chloroformate (CICOOC2H5) (46 mg, 0.42 mmol) and triethylamine (57 mg, 0.57 mmol) may be added. The mixture may be stirred for sufficient duration, e.g. about 2 hours, then N-a-Boc-Lysine 5 (70 mg, 0.28 mmol) in a sufficient volume, e.g. 2 ml of Dimethylformamide (DMF), may be added, and stirred for an additional sufficient duration, e.g. about 2 hours at room temperature (RT). The crude materials may be precipitated in cold diethyl ether (40 ml). Centrifugation for sufficient duration and rpm, e.g. about 5 min at about 3500 rpm, enabled recovery of the pellet which may be purified, e.g. by C18-RP silica chromatography elution with acetonitrile in aqueous NH4HCO3 solution (20 mM) to afford desired product DZ-l-(N-a-Boc)-Lysine as a dark green solid 109 mg (42%). DZ-1-(N- a-Boc)-Lysine may be dissolved in TFA (95%) 5 ml and the mixture may be sufficiently stirred, e.g. about 3 h at ambient temperature, e.g. at RT (about 20 degree centigrade). A sufficient amount of ethyl ether, e.g. 40 ml, may be added. The suspension may be centrifuged for sufficient time to achieve separation, allowing to decant the ether. The product may be dried, e.g.
by placing it under high vacuum for sufficient duration, e.g. overnight. The resulting product 6 may be used without further purification for the steps described below.
[0135] Example 2 - Synthesis of DZ-l-L-CTC conjugates
[0136] Scheme 3 below illustrates one option for synthesizing a DZ-l-L-CTC, here DZ-1- Lysine-CB-TE2A 8:
[0137] Synthesis and radio-labeling of a DZ-1-(L)-CTC, here DZ-l-lysine-CB-TE2A 8 (compare scheme 3): A CTC, here CB-TE2A in a suitable form, e.g. one of its salt, e.g. a HC1 salt, may be mixed with suitable amounts of diisopropylcarbodiimide (DIC) and diisopropylethylamine (DIEA), or alternatively to DIEA, of Et3N. For example, CB-TE2A*4HC1
salt 7 (50 mg, 0.11 mmol), diisopropylcarbodiimide (DIC) (14 mg, 0.11 mmol), and diisopropylethylamine (DIEA) (14 mg, 0.11 mmol) may be dissolved in a suitable volume of DMF, e.g. 2 ml Dimethylformamide (DMF). The mixture may be stirred for a suitable time to ensure complete solution and/or mixing, e.g. about 30 min. To the mixture, DZ-l-L (a conjugate with terminal aminocarboxyl functionality), e.g. DZ-l-Lysine 6 (92 mg, 0.11 mmol) may be added, and stirred for a suitable time to allow for complete reaction, e.g. about 5 hours at room temperature (RT), e.g. about 20 DEG C. The product is precipitated, e.g. in a suitable volume of cold diethyl ether (e.g. about 40 ml). Centrifugation for sufficient time and rpm separates the precipitated product, e.g. for about 5 min at about 3500 rpm. After precipitation, the crude product may be purified by a suitable method, e.g. by C18-RP semi-preparative, to afford the DZ1-L-CTC, here DZ-l-Lysine-CB-TE2A 8, as a dark green solid.
[0139] Radioactive labelling and preparation of a 64Cu-DZ-l-L-CTC, here 64Cu-DZ-l- lysine-CB-TE2A (compare scheme 4): To a reaction vial of suitable volume, e.g. 1.5 ml, the following may be added: about 5 pg of the DZ1-L-CTC, here the DZ-l-Lysine-CB-TE2A 8 in about 200 mΐ of 0.1 M MEOAc (pH about 5.5) solution, about 2 ~ 3 mCi of 64CuCl2 in 0.1 M HC1. The reaction mixture may be carefully mixed, e.g. by shaking, and may be incubated at a suitably elevated temperature for sufficient time to allow for the radioactive labelling to occur, e.g. at about 75°C for about 0.5 h. The 64Cu-DZ-l-lysine-CB-TE2A 9 complex may then be purified by a suitable method, e.g. by reversed-phase HPLC with a suitable column, e.g. an Apollo C18 RP column (5 m, 250 xlO mm). The column eluate may monitored by a suitable method, e.g. by ultraviolet absorbance at a suitable wavelength, e.g. about 254 nm, and/or with a Nal crystal detector. The mobile phase may change from 40% solvent A (e.g. about 0.1% trifluoroacetic acid in about 80% water) and 60% solvent B (e.g. about 0.1% trifluoroacetic acid in about 80% aqueous acetonitrile) to 100% solvent B at suitable time and flow rate, e.g. about 30 min at a flow rate of about 3 ml/min. The pure fraction of the 64Cu-DZ-l-Lysine-CB-TE2A complex separated by HPLC may then be further concentrated and/or dried by gently blowing a positive flow of nitrogen. The residue left in test tube upon concentration may be reconstituted in a suitable volume of a suitable buffer, for example IX PBS buffer (e.g. about 1.0 ml).
[0140] Example 3 - Synthesis of DZ-l-CTC conjugates without linker
[0141] Scheme 5 below illustrates the synthesis of a DZ1-CTC without linker, here DZ-1- DiAmSar:
[0142] Synthesis of DZ-l-DiAmSar (compare scheme 5): A mixture of suitable amounts of DZ-1 4 (e.g. about 50 mg, 0.071mmol), diisopropylcarbodiimide (DIC) (e.g. about 13.5 mg, 0.11 mmol) and hydroxybenzotriazole (HOBt) (e.g. about 11.5 mg, 0.085 mmol) may be dissolved in a suitable amount of DMF, e.g. about 2 ml DMF. The mixture is stirred for a suitable time to allow complete solution and mixing, e.g. about 30 min, then a CTC, here DiAmSar»5H20 10 (29 mg, 0.071 mmol) may be added and stirred for a suitable amount of time to allow for reaction, e.g. about 5 hours at RT. The product may be precipitated in a suitable volume of medium and at a suitably cold temperature to allow for precipitation, e.g. cold diethyl ether (e.g. about 40 ml). The precipitate is separated e.g. by centrifugation at a suitably high rpm for a suitable time, e.g. for about 5 min at about 3500 rpm. The precipitated crude product may be purified by a suitable method, e.g. by C18-RP semi-preparative chromatography, to afford DZ-l-DiAmSar 11 as a dark green solid.
[0143] Scheme 6 below illustrates the radioactive labelling of a DZ-l-CTC, here DZ-1- DiAmSar, and preparation of a 64Cu-DZ-l-CTC, here 64Cu-DZ-l-DiAmSar:
[0144] Preparation of a 64Cu-DZ-l-CTC, here 64Cu-DZ-l-DiAmSar: To a reaction vial of suitable volume, e.g. 1.5 ml, the following may be added: about 5 pg of a DZ1-CTC, here DZ-1- DiAmSar 11 in about 200 mΐ of about 0.1 M NTLtOAc (pH about 5.5) solution, about 2 ~ 3 mCi of 64CUC12 in about 0.1 M HC1. The reaction mixture may be shaken and incubated at a suitable temperature for a suitable time, e.g. about 75°C for about 0.5 h. The 64Cu-DZ-l-DiAmSar 12 complex may be purified by a suitable method, e.g. by Reversed-phase HPLC with a suitable column, e.g. an Apollo C18 RP column (5 m, 250 xlO mm). The column eluate may monitored by a suitable method, e.g. by ultraviolet absorbance at a suitable wavelength, e.g. about 254 nm, and/or with a Nal crystal detector. The mobile phase may change from 40% solvent A (e.g. about 0.1% trifluoroacetic acid in about 80% water) and 60% solvent B (e.g. about 0.1% trifluoroacetic acid in about 80% aqueous acetonitrile) to 100% solvent B at suitable time and flow rate, e.g.
about 30 min at a flow rate of about 3 ml/min. The pure fraction of the 64Cu-DZ-l-DiAmSar complex separated by HPLC may then be further concentrated and/or dried by gently blowing a positive flow of nitrogen. The residue left in test tube upon concentration may be reconstituted in a suitable volume of a suitable buffer, for example IX PBS buffer (e.g. about 1.0 ml).
[0145] For radiolabeling, generally, a suitably radioactive amount and MBq/pg ratio of radiometal may be added to the DZ-1-(L)-CTC conjugates, as will be apparent to a person of ordinary skill. For example the ratio may be up to about 200 MBq/pg (radiometal xonjugate), about 4 to about 100 MBq/pg or about 8 to about 50 MBq/pg e.g. about 20 MBq/pg. For example, 100 MBq (2.7 mCi) of 64Cu to 5 pg of DZ-l-CTC may be added to 0.1N ammonium acetate (pH 5.5) buffer, and the mixture may be incubated at a suitable temperature for a sufficient time to achieve complete labelling, for example at about 20°C to about 60°C, or about 30°C to about 50°C, e.g. at about 40°C for about 10 to about 60 minutes or about 20 to about 40 minutes, e.g. about 30 minutes.
[0146] For example, radiolabeling may be accomplished by addition of about 100 MBq (2.7 mCi) of 64Cu to 5 pg of DZ-1-(L)-CTC in 0.1N ammonium acetate (pH 5.5) buffer, and incubating the mixture at about 40°C for about 30 min. The resulting 64 Cu complex may be purified by Reversed-phase HPLC with an Apollo C18 RP column (5 p, 250 xlO mm). The column eluate may be monitored by ultraviolet absorbance at 254 nm and with a Nal crystal detector. The mobile phase may change from 40% solvent A (0.1% trifluoroacetic acid in 80% water) and 60% solvent B (0.1% trifluoroacetic acid in 80% aqueous acetonitrile) to 100% solvent B at 30 min at a flow rate of 3 ml/min. The pure fraction of the complex from the HPLC may be concentrated by gently blowing a positive flow of nitrogen for drying. The residue left in test tube upon concentration may be reconstituted in a suitable buffer depending on further testing or administration, e.g. IX PBS buffer (1.0 ml).
[0147] Example 4: Superior serum stability of DZ-l-(L)-CTC-64Cu complexes
[0148] The serum stability of the complexes described herein may be determined as follows. A suitable amount, e.g. 50 microcuries of a DZ-l-(L)-CTC-64Cu complex as described herein, e.g.
(e.g., without limitation, DZ-l-Lysine-CB-TE2A, DZ-l-Lysine-DiAmSar, DZ-1-CB-TE2A, DZ-
1-DiAmSar) may be added into a suitable volume, e.g. 100 mΐ, of fetal bovine serum (Invitrogen, Grand Island, NY). After incubation at 37°C for suitable time intervals, e.g. 1, 3, and 6 h, aliquots of the mixture may be removed and filtered, e.g. through a 0.2 mM microspin filter. The resulting filtrates may be analyzed by a suitable separation and detection method, e.g. by reverse- phase HPLC with a Bioscan Flow Count Radio-HPLC detector. The original peak represents an undegraded stable complex. Detection of any newly formed g-peaks in addition to the original peak identifies degraded products and thus a lack of stability of the complex in the serum. For comparison, analysis of DZ-l-Lysine-DOTA-64Cu is performed. DZ-l-Lysine-DOTA-64Cu lacks stability in serum. Due to lesser dissociated 64Cu, the DZ1-(L)-CTC may provide clearer imaging and tumor detection in organs, and a better signal -to-noise ratio. Therapy may be more effective and have lesser side effects.
[0149] Example 5: In vivo stability and protein assays to detect undesirable 64Cu binding
[0150] To determine the stability, or lack thereof, of a radiometal complex in vivo , a gel electrophoresis assay may be performed to detect separate and detect radionuclide-emitting SOD or any other protein, as will be apparent to a person of ordinary skill. If a complex is unstable, upon dissociation, the 64Cu may bind to other proteins, including e.g., without limitation, superoxide dismutase (SOD) in liver, and any assay that allows separating protein-bound 64Cu from complex/conjugate-bound 64Cu and measuring the radionuclide-emission of the protein- bound 64Cu may thus be used to determine a lack of stability and undesirable binding to proteins present in the organs of the body (liver, kidney, etc.). If excessive radiation is determined in particular non-tumorous organs, this may also indicate dissociation and a lack of stability. Similarly, organ-specific assays may be performed, e.g. on mouse or rat liver, kidney etc..
Example 6: PET/microPET imaging of mice with DZ-l-(L)-CTC-64Cu complexes to determine blood clearance and organ distribution.
[0151] Prior to administration to subjects in need thereof, the specificity and tumors tissue penetration of the dye-CTC complexes described herein may be determined by any suitable conventional method, including e.g. PET/CT imaging, e.g. using a suitable animal model, as will be apparent to a person of ordinary skill. For example, a mammalian model such as a mouse
model, in particular, a xenograft mammalian model having the cancer of interest, may be used for testing of the conjugates by imaging, in particular, PET imaging. Other mammalian models may be used, as will be apparent to a person of ordinary skill (e.g. rat, rabbit, dog, monkey, etc.).
[0152] MicroPET imaging (i.e. PET performed on small animals) may be performed as will be apparent to a person of ordinary skill. PET (or microPET) may be performed for imaging and/or therapy or both, to provide image guided therapy. Without wishing to be bound by theory, it is believed that the complexes due to their stability, clearance, efficacy, and advantageous pharmacokinetics are able to provide sufficient tumor uptake and organ clearance to allow for imaging and therapy. Doses may be adjusted for imaging/therapy, or one dose may be suitable for both imaging and therapy.
[0153] The DZ-l-(L)-CTC-64Cu complex (e.g., without limitation, DZ-l-Lysine-CB-TE2A, DZ- 1-Lysine-DiAmSar, DZ-1-CB-TE2A, DZ-l-DiAmSar) may be administered intravenously to individual animals, e.g. mice, e.g. in a suitable number, e.g. a set of five, by injecting a suitable amount, e.g. about 300-500 pCi of the complex. The Transaxial microPET images may be collected in suitable intervals, e.g. hourly, e.g. at 1, 2 and 3 h (and/or 6, 9 and 12h, and/or 12, 24 and 48h, or any combination) post probe injection (pi) time points. The standardized uptake value (SUV) analyses may be performed as will be apparent to a person of ordinary skill, here on on cancer xenografts and muscles of individual mice as defined by CT scans and a tumor-to- muscle ratio may be calculated for each group at these time points, as will be apparent to a person of ordinary skill.
[0154] Blood clearance and organ distribution (e.g., without limitation: liver, kidney, blood, bone, bone marrow, brain) may be determined as follows. After anesthesia (e.g. by isoflurane 2- 3%), a group of mice, e.g. 5 mice, may be injected with one or more 64Cu radiolabeled DZ1-(L)- CTC, e.g. DZ-l-Lysine-CB-TE2A or DZ-l-DiAmSar (e.g. about ~ 5 pCi), e.g. via the tail vein. Retro-orbital blood samples (e.g. 25 pi) may be collected at multiple time points or intervals, e.g. at 5, 15, 30, 60 and 180 min after injection, and radioactivity of all samples may be counted in a gamma counter (e.g. 1480 Wizard™, Perkin-Elmer™) and normalized to plot against injection time, followed by non-linear regression analysis, to determine the half-life time in blood (e.g. by
Prism™ software, e.g. version Prism 9, publicly available from GraphPad™, San Diego, CA). Mice may be sacrificed immediately after the last blood sampling. Tumors and organs (including but not limited to e.g. heart, liver, lung, kidney, small intestine, stomach, bone, bone marrow, muscle, spleen, skin and brain) may be separately harvested and radioactivity may be determined in a gamma counter. Organ distribution data in duplicate may be obtained for each 64Cu complex in mice at multiple time points in suitable time intervals, e.g. at three time points, e.g. at lh, 2h and 3h. Such determination may show a favorable blood and organ clearance for DZ1-(L)-CTC- 64Cu. A comparison of these complexes to other less stable complexes, in particular e.g. to DZ-1- Lys-DOTA-64 complexes, may show superior clearance.
[0155] Image registration and analysis may be performed as follows. PET/CT images may be processed following a standard protocol as will be apparent to a person of ordinary skill, e.g. using standard software as per the manufacturer’s guides, e.g. using the ASIPro™ software, Siemens Healthineers™, Erlangen, Germany. Pixel-wise standardized uptake values (SUVs) of PET may be calculated as a product of the pixel -wise activity divided by the injected dose and body weight. The tumor target may be delineated as 40% of maximum of SUV, anatomically overlaying with a CT image through image registration through the software used.
[0156] 64Cu radiolabeled DZ1-(L)-CTC complexes as described herein are more stable compared to e.g. DZ-l-Lysine-DOTA, also compare example 4, and thus can provide a higher in vivo stability compared to e.g. DZl-Lys-DOTA-64Cu, and/or increased specifity, which may be shown by PET imaging, e.g. the Standardized uptake values (SUV) in the tumor may be improved, tumor retention and/or tumor penetration may be increased e.g. as shown by PET/CT.. DZ1-(L)-CTC-64CU may also advantageously provide a more rapid distribution and clearance that allows improved imaging and therapy and lower side effects. The distribution ratio between tumor and skeletal muscle and thus specificity may be determined by PET as described above and, for example, the tumor-to-muscle ratio after about 24 h of administration may be about 8 : 1 and may be significantly increased by about 20% or more (10:1), about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 100% or more, about 120% or more (20:1), after about 36 to about 48 h of
administration, or longer, as the tumor tissue retains the conjugate for an extended time, and such ratio may exceed that of DZ-l-Lysine-DOTA.
[0157] Example 7: DZ1-(L)-CTC-64CU image-guided radiotherapy/PET, tumor weight reduction and retained body weight in mice, EWS
[0158] Ewing sarcoma (EWS) cell lines and in vivo models may be used to test efficacy against EWS, in particular against disseminated or recurrent EWS.
[0159] To assess the therapeutic effects, efficacy and toxicity of DZ1-(L)-CTC-64CU, nude mice may be inoculated subcutaneously with human EWS cancer cells (e.g. ATCC® CRL-2971™, publicly available e.g. from ATCC). The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
[0160] ATCC® CRL-2971™ is a human clear cell sarcoma cell line with an EWS/ATF1 fusion gene produced by a consistent t(12;22)(ql3;ql2) chromosomal translocation.
[0161] Subsequently, nude mice with a subcutaneous tumor size of e.g. about -100 mm3 may be randomly assigned to several groups (e.g. n = 5 mice per group). For the therapeutic group, tumor-bearing mice will be administered intravenously (e.g. via the tail vein) with a suitable amount and volume for a suitable duration, e.g. about 0.2 ml of a DZ1-(L)-CTC-64CU (e.g. about 5.55 GBq/kg). The treatment may be given in regular intervals, e.g. once a day or week for several days or weeks, e.g. once a week for 4 weeks. With the same treatment scheme, a control group may be injected via tail vein with vehicle solvent (e.g. saline of the same volume, e.g. about 0.2 ml). After the treatment, mice may be kept for another period, e.g. about 12 weeks. Endpoint of the study will be differential tumor growth between treatment and control group. Body weight may be monitored throughout.
[0162] Alternatively the therapeutic effects, efficacy and toxicity of DZ1-(L)-CTC-64CU may be determined essentially using nude mice as described above except that inoculating with human
cancer cells is performed intracranially, to determine crossing of the blood-brain-barrier, and the endpoint of the study will be differential animal death between treatment and control group. Body weight may be monitored throughout.
[0163] Tumor specific targeting may be determined with one or more methods, e.g. 1) near infrared fluorescence tumor imaging to detect accumulation of the DZ-1 moiety in the tumor, 2) SPECT/CT nuclear imaging in the same tumor, and/or 3) PET imaging (also see PET described herein-above). PET and SPECT imaging may determine higher clearance and a better signal-to- noise ratio, and allow for image-guided therapy. Tumor dimensions may be measured in regular intervals, e.g. daily or once or twice weekly, with a suitable method such as with calipers, e.g. digital calipers, and the tumor volume may be calculated using the formula: volume = 1/2 (length x width x width). To monitor potential toxicity, body weight may be measured. Mice may be euthanized when the tumor size exceeded the volume of 1,500 mm3 or the body weight lost >20% of original weight. Complexes as described herein may advantageously show a decreased tumor weight, indicative of efficacy, and retained body weight and indicative of a lack of toxicity, in contrast to e.g. DZ1-L-DOTA-64CU.
[0164] Example 8: Image-guided therapy of prostate cancer
[0165] Male nude mice of 4 - 6 weeks of age may be inoculated subcutaneously with human prostate cancer cells, e.g. C4-2B (also known as ATCC® CRL-3315™ and publicly available from American Type Culture Collection (ATCC), Manassas, Virginia) or ARCaPM, publicly available from Novicure™, Birmingham, AL (ARCaPM cells, Catalog Number: 3422, are human prostate cancer cells established from a parental mixed ARCaP cell population with high propensity for bone metastasis in mice. Histopathology of the tumors in bone is mainly of osteoblastic lesions that recapitulate human prostate cancer bone metastasis. ARCaPM cells (spindle-shape mesenchymal morphology) were derived by single cell cloning of the parental ARCaP cells. ARCaPM are highly aggressive prostate cancer metastatic cells. In one study, the incidence of bone metastasis for ARCaPM cells, after intracardiac injection, was determined to be 100% (9/9) with a respective latent period of 71- and 61 -days. ARCaPM cells can grow in culture using MCaP culture Medium available from Novicure™. ARCaPM cells may be used to
study prostate cancer bone metastasis and the role of EMT in cancer metastasis. MCaP -medium was prepared using Dulbeccos modified eagle and F12K medium and contains essential and non- essential amino acids, vitamins, organic and inorganic compounds, hormones, growth factors and trace minerals and supplemented with several factors that are critical for the optimal growth of ARCaP cells in vitro. The medium is serum-free and should be supplemented with 5% heat- inactivated Fetal Bovine Serum. It is bicarbonate buffered and has a pH of 7.4 when equilibrated in an incubator with an atmosphere of 5% C02/95% air).
[0166] The mice may be kept for a suitably long duration, e.g. 2 weeks, for tumor formation to about 100 mm3 in volume. The probe solution for injection will be prepared in sterile phosphate buffered saline (PBS) (radioactive doses of probe DZ-l-Lysine-CTC-64Cu complex). Mice may be administered intravenously (e.g. via tail vein) with the imaging probe in a suitable volume (e.g. a volume of about 100-150 pi), followed by procedures of blood collection, probe biodistribution, and fluorescence and PET imaging under inhalation anesthesia (e.g. 2% isoflurane in oxygen), as will be apparent to a person of ordinary skill.
[0167] As a first optional step, complexes as described herein may be administered e.g. as described herein to detect a primary tumor, and/or may be used to detect any residual metastases or secondary tumors thereof, e.g. after removal of a primary tumor, e.g. by surgery.
[0168] Therapy and/or imaging may be performed in parallel or subsequently on a first and/or one or more secondary tumor, or metastases of a first or one or more secondary tumor using the complexes as described herein, optionally with parallel detection/imaging of residual metastases/tumors, and optionally followed by a first or further tumor therapy, or in case a first tumor therapy has been performed, a second or further tumor therapy and/or image-guided radiotherapy/detection of metastases/secondary tumors by imaging. Complexes as described herein may be particularly advantageous for imaging, therapy, and/or image-guided therapy of prostate cancer, including e.g. an improved serum stability, reduced toxicity, and significantly reduced metastatic bone tumor formation.
[0169] Example 9: Image-guided therapy of brain tumors including glioblastoma
[0170] To determine tumor suppression efficacy and/or animal survival and/or body weight etc., experiments may be essentially performed as described herein-above under example 2. For example, to assess tumor suppression efficacy, nude mice may be inoculated subcutaneously with human brain cancer cells (e.g. neuroblastoma, astrocytoma, or glioblastoma cells, publicly available from ATCC, e.g., without limitation, CRL-2271, CRL-2268, CRL-7674, and CRL- 7514 (neuroblastoma, human); HTB-12, HTB-13, HTB-14, HTB-17, CRL-7769, CRL-7903 (astrocytoma, human), HTB-15, HTB-16, CRL-2611, CRL-11543, CRL-11544 (glioblastoma, human)). Subsequently, nude mice with subcutaneous tumor size of -100 mm3 may be randomly assigned to several groups (e.g. n = 5 mice per group). To assess the efficacy on animal survival, the therapeutic effects, efficacy and toxicity may be determined by inoculating nude mice intracranially with human brain cancer cells (e.g. neuroblastoma, astrocytoma, or glioblastoma cells publicly available from ATCC). One week after inoculation, the subject mice will be randomly assigned to several groups (e.g. n = 5 mice per group).
[0171] The probe solution for injection may be prepared in sterile PBS buffer. Mice may be administered intravenously (via tail vein) with imaging probes (PBS volume e.g. 100-150 pi) for blood collection, probe biodistribution, and fluorescence and PET imaging by intravenous injection e.g. via the mouse tail vein, e.g. using a syringe (e.g. 1/2 cc U-100 Insulin Syringe) under inhalation anesthesia (2% isoflurane in oxygen). Radioactive doses, also known as probe, may be the DZ-1-(L)-CTC 64 Cu complex, formed as will be apparent to a person of ordinary skill and as generally described herein-above.
[0172] One or more treatment administrations, optionally preceded or followed by one or more imaging step administration may be generally performed as described in example 5 herein above, with the following adjustments: The probe solution for injection may be prepared in sterile PBS buffer. Mice may be administered with imaging probes (PBS volume 100-150 mΐ) for blood collection, probe biodistribution, and fluorescence and PET imaging e.g. by intravenous injection e.g. via mouse tail vein e.g. using a syringe (e.g. 1/2 cc U-100 Insulin Syringe) under anesthesia (2% isoflurane in oxygen).
[0173] In a first step, a brain tumor that is inoculated in the subcutaneous space may be surgically removed, optionally after detection using 64Cu complexes as described herein. In a second step, residual disease may be determined post-surgery and/or at intervals after surgery to detect resurgence using 64Cu complexes as described herein. Treatment may be in parallel at the same dose, or altematively/additionally, upon detection of residual or resurgent metastases or tumors, treatment and prolonged and optionally higher dosed 64Cu complexes may be initiated.
[0174] Similarly, in animals bearing an intracranial brain tumor, the tumor may be detected with 64Cu complexes as described herein, and may be administered in a therapeutic dose to prevent or slow tumor growth, prevent or postpone animal death, and/or cause tumor shrinkage.
[0175] Example 10: Stability and specificity of DZ-l-Lys-CB-TE2A with Copper-64
[0176] Radiolabeling with 64 Cu may be performed as follows.
[0177] 37.5 pg DZ-l-Lys-CB-TE2A in 7.5 pL ethanol is added to a 0.4 M NaOAc solution (pH 5.5) containing 4.9 mCi of 64Cu(II). The solution mixture is heated to 65°C while being stirred and the temperature was maintained for 30 min. The reaction is run in the darkness and sampled to test the progress of the radiolabeling by radio-TLC (50 mM DTPA solution incubation 10 min; iTLC-SG plate, lx PBS as mobile phase). The radiochemical purity (RCP) of 64Cu-DZ-l- Lys-CB-TE2A is measured by radio-HPLC (62% A to 20% in 15min, lmL/min; A: lOmM NH40Ac, B: acetonitrile; Atlantis T3 column, 4.6*150nm, 3 pm). The HPLC fractions from 10 - 12 min are collected and pooled (RCP > 95%) for the following biological evaluation experiments.
[0178] Radio-HPLC analysis of 64Cu-DZ-l-Lys-CB-TE2A is shown in Fig. 1, with the top showing the UV channel at 780 nm, and the bottom showing the radio-channel.
[0179] A serum stability assay may be performed as follows.
[0180] Stability may be measured by radio-TLC in serum at 37°C. To 95 pL of serum 5 pL of 64Cu-DZ-l-Lys-CB-TE2A is added. The mixture was incubated at 37°C for 48 h. At time points
of 2 h, 6 h, 24 h, and 48 h, the mixture was sampled for radio-TLC analysis, in which 400 pL of 50mM DTPA solution was used each time to assess the extent of 64Cu dissociation from 64Cu- DZ-l-Lys-CB-TE2A.
[0181] As shown in Fig. 2, the stability of 64Cu-DZ-l-Lys-CB-TE2A in serum maintained more than about 95% intact until at least about 48 h in serum at about 37°C.
[0182] In vivo PET imaging evaluation of 64Cu-DZ-l-Lys-CB-TE2A may be performed as follows.
[0183] Studies in animal models, e.g. mouse, may be performed as follows.
[0184] Cancer cell lines, in particular, human cancer cell lines, more specifically prostate cancer cell lines such as human DU145 prostate cancer cell lines, e.g. DU145vc (PTPN1 WT) and DU145sh (PTPN1 knockdown (KD)), may be obtained from the American Type Culture Collection (ATCC). With regard to PTPN1 KD, its expression is upregulated in androgen receptor (AR)-negative prostate cancer (e.g., castration-resistant prostate cancer) as compared to AR-positive prostate cancer.
[0185] These or other cancer cell lines may be used to establish cancer xenograft models in suitable mice, in particular in SCID mice. For example, prostate cancer xenograft models in SCID mice may be used. About ~ 1 x 106 cell suspensions of DU145vc and DU145sh may be injected subcutaneously, e.g. into the right and left shoulders of SCID mice, respectively. Post injection, mice are monitored for tumor growth in regular intervals.
[0186] DU145vc and DU145sh tumors started growing three weeks post-injection. DU145vc tumors grew much quicker than DU145sh. When DU145sh became palpable, the size of DU145vc was already in the range of 500 - 1000 mm3.
[0187] Small animal PET/CT Imaging may be performed as follows.
[0188] The imaging study may start at tumor sizes of about 500 mm3 or larger and may be performed on a suitable PET/CT imaging system, e.g. on a Siemens Inveon PET/CT
Multimodality System (Knoxville, TN). Here, DU145sh tumor size at the start was about 500 to about 1,000 mm3, while DU145vc tumor size was between about 1,000 mm3 to about 2,000 mm3. PET is followed by CT data acquisition, which may be conducted at 80 kV and 500 mA with a focal spot of 58 pm. Static scans may be performed at suitable intervals, e.g. at 4 h, 24, and 48 h post-injection of e.g. about ~ 100 pCi of 64Cu-DZ-l-Lys-CB-TE2A in 100 pL saline containing < 1% ethanol into each tumor-bearing mouse under anesthesia with 2% isoflurane in oxygen (at each time point, n = 2). Both CT and PET images are reconstructed with the manufacturer’s software. Reconstructed CT and PET images are fused for quantitative data analysis. Regions of interest (ROIs) were drawn as guided by CT and quantitatively expressed as standardized uptake values (SUV).
[0189] As shown in Fig. 3, Fig. 4 A-C and Fig. 5 A-C, for 64Cu-DZ-l-Lys-CB-TE2A, substantial tumor uptake, good signal-to-noise ratio, high specificity and suitable clearance within 48 h to below 0.25 Standardized Uptake Value (SUV) is observed in both mouse models bearing DU145vc (WT - left shoulder) and DU145sh (PTPN1 KD - Right shoulder) xenografts. SUV range from about 2.5 or more at 4h to between about 0.5 to about 2.5 at 24h, and about 0.125 at 48h, see in particular Fig. 3. This shows sample signal strength within a practical time frame for imaging from about 4 h to about 24 hours or more, or 48 hours or more (note tumor retention with sufficient signal strength at maximum intensity even at about 48 hours, see in particular Fig. 5 C). Of note, 64Cu-DZ-l-Lys-CB-TE2A also exhibited an efficient clearance profile from the kidneys, which is a high desirable feature, in particular for a copper radiotheranostic, compare in particular Fig. 4 B and Fig. 4C; these images at 24 h (B) and 48 h (C) post-injection are presented at the same signal intensity scale to show efficient renal clearance. In Fig. 5 A-C the three time point images are presented on different scales in the format of maximum intensity projection (MIP) which demonstrates the uptake and retention of 64Cu-DZ-l-CB-TE2A in tumors. An excellent target-to-background ratio and a high specificity is notable.
[0190] Example 11: Comparative example with 64Cu-DZ-l-NOTA shows its lack of specificity
[0191] The formula for DZ-l-NOTA-64Cu is shown below.
DZ- 1 -NQTA-64Cu
[0192] The experiment is performed essentially as described herein-above using a PC3 subcutaneous model (small tumor volume<100 mm3), and 64Cu-DZ-l-NOTA (-100 uCi/animal). SCID mice were inoculated subcutaneously with lx lO6 PC3 cells. PC3 or PC-3 is a cell line initiated from a bone metastasis of a grade IV prostatic adenocarcinoma that is publicly available from ATCC (CRL-1435™). An IV injection is given and images are taken at various time points post-injection, as indicated (6, 24, 48h). A standardized uptake value (SUV) is calculated based on isotope activity (from PET)/ volume of region of interest (from CT) /body weight and is shown for the tumor in Fig. 6 and Fig. 7A, Fig. 7B, and Fig. 7C. The SUV was about 0.3 at 6 hours p.i., increased to about 0.4 SUV at 24h p.i. and decreased to about 0.3 at 48h. A low target-to-background ratio is notable, see Fig. 7A, Fig. 7B, and Fig. 7C, and a low specificity of the 64Cu-DZ-l-NOTA is observed .
[0193] Complexes described herein may be particularly advantageous for imaging, therapy, and/or image-guided therapy of glioblastoma, including e.g. an improved serum stability, while retaining the ability to cross the blood-brain-barrier to improve animal survival.
[0194] Many suitable methods to make or use the complexes described herein are known in the art. According to an embodiment of the present invention, the complexes may be used for cancer
therapy as described herein-above. Many different options of administration and treatments are available and can be selected and applied depending on the individual subject and determined treatment protocol, as will be apparent to a person of ordinary skill. Features of one embodiment may be employed with other embodiments as the skilled artisan would recognize, even if not explicitly stated herein. Descriptions of well-known components and processing techniques may be omitted so as to not unnecessarily obscure the embodiments.
[0195] While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from this detailed description. The invention is capable of myriad modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the descriptions are to be regarded as illustrative in nature rather than restrictive.
Claims
1. A DZ-1-(L)-CTC conjugate, wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with an optional linker moiety L and a cross-bridged tetraamine cyclam (CTC) chelator residue R and as shown in FI below:
wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from the group consisting of CB-TE2A, DiAmSar, or a derivative thereof, and wherein the chelator residue is complexed with 64Cu.
2. The complex of claim 1 wherein R is CB-TE2A, and wherein L is a lysine residue which links DZ-1 to the chelator as shown in FII below:
(DZl-DiAmSar).
4. The complex of claim 1 provided with one or more pharmaceutically acceptable excipient to form a pharmaceutical formulation.
5. The complex of claim 4, provided as a kit with one or more reagents for reconstitution of the complex in an administrable form.
6. The complex of claim 5, wherein the kit is provided with instructions for mixing and complexing the conjugate and 64Cu in suitable amounts, optionally with one or more reagent, buffer or excipient, and optionally treating the resulting solution containing the formed complex to provide it in an administrable form.
7. A method for imaging or treating cancer wherein a DZ-l-Lys-chelator conjugate complex of formula FI is administered to a subject suffering from cancer or from a risk to develop cancer in a sufficient amount and for sufficient duration to allow imaging or treatment; wherein the conjugate comprises a heptamethine carbocyanine dye (HMCD) moiety conjugated with a chelator residue R via a lysine linker and as shown in formula FI below:
wherein wherein L comprises one or more aminoacid residue, or alternatively, linker L is absent, and wherein the chelator forming the chelator residue R is selected from CB-TE2A, DiAmSar, or a derivative thereof, and wherein the chelator residue is complexed with 64Cu.
8. The method of claim 7 wherein R is CB-TE2A, and wherein L is a lysine residue which links DZ-1 to the chelator as shown in FII below:
(DZl-DiAmSar).
10. The method of claim 7, wherein imaging is performed by Positron Emission Tomography (PET) or Single-Photon Emission Computerized Tomography (SPECT) to detect 64Cu radiation, and optionally additionally by Computer Tomography (CT).
11. The method of claim 7, wherein imaging is performed before and/or during one or more therapy time intervals to provide an image-guided therapy.
12. The method of claim 7, wherein the risk to develop cancer is one or more genetic alteration associated with EWS, and the alterations include one or more alteration to a member of the ETS family of transcription factors.
13. The method of claim 7, wherein the cancer is selected from the group comprising:
Ewing’s Sarcoma (EWS), a small cell round tumor, adult neuroblastoma, neuroblastoma
in children, small cell lung cancer, Merkel cell tumors, Merkel cell tumors of the skin, prostate cancer, hormone-refractory prostate cancer (HRPC), neuroendocrine differentiated HRPC (NE-HRPC), pre-B-cell acute lymphoblastic leukemia, and a cancer which is associated with alterations in one or more member of the ETS family of transcription factors.
14. The method of claim 10, wherein the cancer is Ewing’s Sarcoma (EWS).
15. The method of claim 7, wherein R is CB-TE2A, or a derivative thereof.
16. The method of claim 7, wherein R is DiAmSar, or a derivative thereof.
17. The invention substantially as described herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163159207P | 2021-03-10 | 2021-03-10 | |
US63/159,207 | 2021-03-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022192503A1 true WO2022192503A1 (en) | 2022-09-15 |
Family
ID=83227057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/019695 WO2022192503A1 (en) | 2021-03-10 | 2022-03-10 | Heptamethine carbocyanine dye-cross-bridged tetraamine cyclam (ctc) chelator conjugates, their stable complexes with copper-64, and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022192503A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013052776A1 (en) * | 2011-10-07 | 2013-04-11 | Cedars-Sinai Medical Center | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties |
US20160199520A1 (en) * | 2013-09-24 | 2016-07-14 | Fujifilm Corporation | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
US20190269783A1 (en) * | 2016-10-21 | 2019-09-05 | Cedars-Sinai Medical Center | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors |
-
2022
- 2022-03-10 WO PCT/US2022/019695 patent/WO2022192503A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013052776A1 (en) * | 2011-10-07 | 2013-04-11 | Cedars-Sinai Medical Center | Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties |
US20160199520A1 (en) * | 2013-09-24 | 2016-07-14 | Fujifilm Corporation | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
US20190269783A1 (en) * | 2016-10-21 | 2019-09-05 | Cedars-Sinai Medical Center | Compounds and methods to sensitize cancer cells to tyrosine kinase inhibitors |
Non-Patent Citations (2)
Title |
---|
CROMPTON BRIAN D., STEWART CHIP, TAYLOR-WEINER AMARO, ALEXE GABRIELA, KUREK KYLE C., CALICCHIO MONICA L., KIEZUN ADAM, CARTER SCOT: "The Genomic Landscape of Pediatric Ewing Sarcoma", CANCER DISCOVERY, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, no. 11, 1 November 2014 (2014-11-01), US , pages 1326 - 1341, XP055969407, ISSN: 2159-8274, DOI: 10.1158/2159-8290.CD-13-1037 * |
LEE ET AL.: "Peptides and Peptide Hormones for Molecular Imaging and Disease Diagnosis", CHEM. REV., vol. 110, 2010, pages 3087 - 3111, XP002644588, DOI: 10.1021/CR900361P * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6556805B2 (en) | Labeled inhibitor of prostate specific membrane antigen (PSMA), imaging agent for the treatment of prostate cancer and its use as a medicament | |
JP7500551B2 (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents, and pharmaceutical agents for the treatment of psma-expressing cancers - Patents.com | |
Shi et al. | Evaluation of 111In-labeled cyclic RGD peptides: effects of peptide and linker multiplicity on their tumor uptake, excretion kinetics and metabolic stability | |
ES2960729T3 (en) | 177 Lu-dota-hynic-ipsma as a therapeutic radiopharmaceutical targeting prostate-specific membrane antigen | |
JP2021506784A (en) | Complex containing PSMA targeting compound linked to lead or thorium radionuclide | |
ligan et al. | 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals | |
WO2022218409A1 (en) | Heptamethylcarbocyanine dye - crosslinked tetracyclic amine chelating agent conjugate, and complex thereof and use thereof | |
JP7447300B2 (en) | DZ-1-Lys-DOTA conjugate and use in combination with radioactive metals | |
US20220211884A1 (en) | Rk polypeptide radiopharmaceutical targeting her2 and preparation method thereof | |
Xia et al. | Comparative evaluation of 68 Ga-labelled TATEs: the impact of chelators on imaging | |
WO2022147224A1 (en) | Heptamethine carbocyanine dye-dota conjugates complexed with lutetium-177, yttrium-90, or gallium-68, and their uses for image-guided radiotherapy | |
CN115745903B (en) | Peptide urea derivative, pharmaceutical composition containing same and application of peptide urea derivative | |
WO2023143612A1 (en) | Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative | |
WO2022192503A1 (en) | Heptamethine carbocyanine dye-cross-bridged tetraamine cyclam (ctc) chelator conjugates, their stable complexes with copper-64, and uses thereof | |
WO2021175147A1 (en) | Prostate-specific membrane antigen-binding ligand conjugate and application thereof | |
JP2005047821A (en) | Diagnostic or therapeutic medicine using cyclopentadienyl carbonyl group-containing radiactive compound | |
WO2010125647A1 (en) | Radioactively labeled substance | |
US20230173112A1 (en) | PSMA-Targeting Ligands With Optimal Properties for Imaging and Therapy | |
KR102374087B1 (en) | Immuno-conjugates and uses thereof | |
Lahnif | Development of novel small-molecule drug conju-gates for imaging and treatment of prostate cancer | |
WO2020045638A1 (en) | Radioactive imidazothiadiazole derivative compound | |
JP2024099559A (en) | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents, and pharmaceutical agents for the treatment of psma-expressing cancers - Patents.com | |
Lewis et al. | Evaluation of a bimodal, matched pair theranostic agent targeting prostate-specific membrane antigen | |
JP2024518097A (en) | Folate receptor-targeted conjugates with brush border membrane enzyme-cleavable linkers and methods of use in cancer imaging and therapy - Patents.com | |
WO2017030893A1 (en) | Method of imaging with a chelating compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22767967 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22767967 Country of ref document: EP Kind code of ref document: A1 |